GB8308235D0
(en)
*
|
1983-03-25 |
1983-05-05 |
Celltech Ltd |
Polypeptides
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
WO1986005513A1
(en)
*
|
1985-03-18 |
1986-09-25 |
Gene Labs, Inc. |
Hybrid-gene cassette vector
|
US5169939A
(en)
*
|
1985-05-21 |
1992-12-08 |
Massachusetts Institute Of Technology & Pres. & Fellows Of Harvard College |
Chimeric antibodies
|
EP0536566A1
(de)
*
|
1985-11-01 |
1993-04-14 |
Xoma Corporation |
Modulare Einheit von Antikörpergenen, daraus hergestellte Antikörper und Verwendung
|
US5618920A
(en)
*
|
1985-11-01 |
1997-04-08 |
Xoma Corporation |
Modular assembly of antibody genes, antibodies prepared thereby and use
|
EP0247091B1
(de)
*
|
1985-11-01 |
1993-09-29 |
Xoma Corporation |
Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung
|
US5576195A
(en)
*
|
1985-11-01 |
1996-11-19 |
Xoma Corporation |
Vectors with pectate lyase signal sequence
|
US5225539A
(en)
*
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
GB8607679D0
(en)
*
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
GB2188941B
(en)
*
|
1986-04-14 |
1990-06-06 |
Bayer Ag |
Monoclonal antibodies recognizing human interleukin-2-receptor
|
DE3751908T2
(de)
*
|
1986-07-07 |
1997-02-06 |
Centocor Inc |
Chimärisches Murine-Mensch-Immunoglobulin, spezifisch für tumorassoziertes 17-1A Antigen
|
US4954617A
(en)
*
|
1986-07-07 |
1990-09-04 |
Trustees Of Dartmouth College |
Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
|
US5260203A
(en)
*
|
1986-09-02 |
1993-11-09 |
Enzon, Inc. |
Single polypeptide chain binding molecules
|
US5869620A
(en)
*
|
1986-09-02 |
1999-02-09 |
Enzon, Inc. |
Multivalent antigen-binding proteins
|
US4946778A
(en)
*
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
IL84285A
(en)
*
|
1986-10-27 |
1993-03-15 |
Int Genetic Engineering |
Chimeric antibody with specificity to human tumor antigen
|
US6893625B1
(en)
|
1986-10-27 |
2005-05-17 |
Royalty Pharma Finance Trust |
Chimeric antibody with specificity to human B cell surface antigen
|
CA1339445C
(en)
*
|
1986-11-12 |
1997-09-09 |
The General Hospital Corporation |
Recombinant hybrid immunoglobulin molecules and method of use
|
IL85035A0
(en)
*
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
ATE151638T1
(de)
|
1987-02-20 |
1997-05-15 |
Genentech Inc |
Verfahren und zubereitungen für die verwendung von hiv-env-polypeptiden und antikörpern
|
DE3800048A1
(de)
*
|
1987-05-14 |
1988-11-24 |
Boehringer Mannheim Gmbh |
Verfahren zur bestimmung eines antikoerpers in menschlichen koerperfluessigkeiten
|
US5258498A
(en)
*
|
1987-05-21 |
1993-11-02 |
Creative Biomolecules, Inc. |
Polypeptide linkers for production of biosynthetic proteins
|
DE3853515T3
(de)
*
|
1987-05-21 |
2005-08-25 |
Micromet Ag |
Multifunktionelle proteine mit vorbestimmter zielsetzung.
|
US5091513A
(en)
*
|
1987-05-21 |
1992-02-25 |
Creative Biomolecules, Inc. |
Biosynthetic antibody binding sites
|
US5132405A
(en)
*
|
1987-05-21 |
1992-07-21 |
Creative Biomolecules, Inc. |
Biosynthetic antibody binding sites
|
US5981278A
(en)
*
|
1987-05-29 |
1999-11-09 |
Tanox, Inc. |
Chimeric monoclonal antibodies which neutralize HIV-1 infection and their applications in therapy and prevention for AIDS
|
US6657050B1
(en)
|
1987-05-29 |
2003-12-02 |
Tanox, Inc. |
Chimeric viral-neutralizing immunoglobulins
|
US5834599A
(en)
*
|
1987-05-29 |
1998-11-10 |
Tanox Biosystems, Inc. |
Immunoconjugates which neutralize HIV-1 infection
|
CA1341235C
(en)
*
|
1987-07-24 |
2001-05-22 |
Randy R. Robinson |
Modular assembly of antibody genes, antibodies prepared thereby and use
|
JPS6439990A
(en)
*
|
1987-08-05 |
1989-02-10 |
Chisso Corp |
Fused gene by bonding aequorin gene to functional gene
|
US5677425A
(en)
*
|
1987-09-04 |
1997-10-14 |
Celltech Therapeutics Limited |
Recombinant antibody
|
GB8720833D0
(en)
*
|
1987-09-04 |
1987-10-14 |
Celltech Ltd |
Recombinant dna product
|
US5202238A
(en)
*
|
1987-10-27 |
1993-04-13 |
Oncogen |
Production of chimeric antibodies by homologous recombination
|
US4978745A
(en)
*
|
1987-11-23 |
1990-12-18 |
Centocor, Inc. |
Immunoreactive heterochain antibodies
|
US5428133A
(en)
*
|
1987-12-31 |
1995-06-27 |
Tanox Biosystems, Inc. |
Chimeric anti-human IgE-monoclonal antibody which binds to secreted IgE and membrane-bound IgE expressed by IgE-expressing B cells but notto IgE bound to FC receptors on basophils
|
US5449760A
(en)
*
|
1987-12-31 |
1995-09-12 |
Tanox Biosystems, Inc. |
Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
|
US5843708A
(en)
*
|
1988-01-05 |
1998-12-01 |
Ciba-Geigy Corporation |
Chimeric antibodies
|
GB8800077D0
(en)
*
|
1988-01-05 |
1988-02-10 |
Ciba Geigy Ag |
Novel chimeric antibodies
|
US5567584A
(en)
*
|
1988-01-22 |
1996-10-22 |
Zymogenetics, Inc. |
Methods of using biologically active dimerized polypeptide fusions to detect PDGF
|
US5750375A
(en)
*
|
1988-01-22 |
1998-05-12 |
Zymogenetics, Inc. |
Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
|
EP0325224B1
(de)
*
|
1988-01-22 |
1996-07-31 |
ZymoGenetics, Inc. |
Verfahren zur Herstellung von sekretierten Rezeptoranalogen
|
US6018026A
(en)
|
1988-01-22 |
2000-01-25 |
Zymogenetics, Inc. |
Biologically active dimerized and multimerized polypeptide fusions
|
US5846534A
(en)
*
|
1988-02-12 |
1998-12-08 |
British Technology Group Limited |
Antibodies to the antigen campath-1
|
AU3342689A
(en)
*
|
1988-03-24 |
1989-10-16 |
Igen Incorporated |
Luminescent chimeric proteins
|
USRE39760E1
(en)
*
|
1988-03-31 |
2007-08-07 |
International Bio-Immune Systems Inc. |
Monoclonal antibodies against human colon carcinoma-associated antigens and uses therefor
|
US5372812A
(en)
*
|
1988-04-04 |
1994-12-13 |
The General Hospital Corporation |
Composition and method for acceleration of clot lysis
|
US5582862A
(en)
|
1988-04-04 |
1996-12-10 |
General Hospital Corporation |
Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
|
US4975369A
(en)
*
|
1988-04-21 |
1990-12-04 |
Eli Lilly And Company |
Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
|
IL86278A
(en)
*
|
1988-05-04 |
2003-06-24 |
Yeda Res & Dev |
Endowing cells with antibody specificity using chimeric t cell receptor
|
US5906936A
(en)
*
|
1988-05-04 |
1999-05-25 |
Yeda Research And Development Co. Ltd. |
Endowing lymphocytes with antibody specificity
|
US5770198A
(en)
*
|
1988-05-18 |
1998-06-23 |
The Research Foundation Of The State Of New York |
Platelet-specific chimeric 7E3 immunoglobulin
|
US5609869A
(en)
*
|
1988-08-19 |
1997-03-11 |
The General Hospital Corporation |
Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
|
US5811265A
(en)
*
|
1988-08-19 |
1998-09-22 |
The General Hospital Corporation |
Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
|
DE68913658T3
(de)
|
1988-11-11 |
2005-07-21 |
Stratagene, La Jolla |
Klonierung von Immunglobulin Sequenzen aus den variablen Domänen
|
WO1990006323A2
(en)
*
|
1988-11-29 |
1990-06-14 |
Centocor, Inc. |
Chimeric proteins incorporating a metal binding protein
|
DE3900534A1
(de)
*
|
1989-01-10 |
1990-07-12 |
Boehringer Mannheim Gmbh |
Diagnostischer nachweis unter verwendung von chimaeren antikoerpern
|
US6309880B1
(en)
*
|
1989-04-25 |
2001-10-30 |
Tanox, Inc. |
Antibodies specific for CD4-binding domain of HIV-1
|
US6291158B1
(en)
|
1989-05-16 |
2001-09-18 |
Scripps Research Institute |
Method for tapping the immunological repertoire
|
US6291160B1
(en)
*
|
1989-05-16 |
2001-09-18 |
Scripps Research Institute |
Method for producing polymers having a preselected activity
|
US6969586B1
(en)
|
1989-05-16 |
2005-11-29 |
Scripps Research Institute |
Method for tapping the immunological repertoire
|
US6291159B1
(en)
*
|
1989-05-16 |
2001-09-18 |
Scripps Research Institute |
Method for producing polymers having a preselected activity
|
US6291161B1
(en)
*
|
1989-05-16 |
2001-09-18 |
Scripps Research Institute |
Method for tapping the immunological repertiore
|
US6680192B1
(en)
|
1989-05-16 |
2004-01-20 |
Scripps Research Institute |
Method for producing polymers having a preselected activity
|
US6020145A
(en)
*
|
1989-06-30 |
2000-02-01 |
Bristol-Myers Squibb Company |
Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
|
IL94872A
(en)
*
|
1989-06-30 |
1995-03-30 |
Oncogen |
Monoclonal or chimeric antibodies that react with human carcinoma, recombinant proteins that contain their anti-binding site, pharmaceutical preparations and kits that contain the
|
US5998378A
(en)
*
|
1989-08-16 |
1999-12-07 |
Chiron Corporation |
Compositions for the inhibition of TNF hormone formation and uses thereof
|
US6586222B1
(en)
|
1989-08-16 |
2003-07-01 |
Chiron Corporation |
Recombinant PR-3 and compositions thereof
|
US5843693A
(en)
*
|
1989-08-16 |
1998-12-01 |
Chiron Corporation |
Assay method for screening for inhibitors of proTNF conversion
|
US5196320A
(en)
*
|
1989-09-20 |
1993-03-23 |
Abbott Biotech, Inc. |
Method of producing engineered binding proteins
|
US6750325B1
(en)
|
1989-12-21 |
2004-06-15 |
Celltech R&D Limited |
CD3 specific recombinant antibody
|
US7037496B2
(en)
|
1989-12-27 |
2006-05-02 |
Centocor, Inc. |
Chimeric immunoglobulin for CD4 receptors
|
US5314995A
(en)
*
|
1990-01-22 |
1994-05-24 |
Oncogen |
Therapeutic interleukin-2-antibody based fusion proteins
|
GB9021671D0
(en)
*
|
1990-10-05 |
1990-11-21 |
Unilever Plc |
Delivery of agents
|
US5349053A
(en)
*
|
1990-06-01 |
1994-09-20 |
Protein Design Labs, Inc. |
Chimeric ligand/immunoglobulin molecules and their uses
|
EP0460607A3
(en)
*
|
1990-06-05 |
1992-04-01 |
Bristol-Myers Squibb Company |
Novel monoclonal antibody to novel antigen associated with human tumors
|
GB9020282D0
(en)
|
1990-09-17 |
1990-10-31 |
Gorman Scott D |
Altered antibodies and their preparation
|
US5958413A
(en)
*
|
1990-11-01 |
1999-09-28 |
Celltech Limited |
Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor
|
US6399062B1
(en)
*
|
1990-11-06 |
2002-06-04 |
The United States Of America As Represented By The Secretary Of The Navy |
Murine monoclonal antibody protective against Plasmodium vivax malaria
|
US5650150A
(en)
*
|
1990-11-09 |
1997-07-22 |
Gillies; Stephen D. |
Recombinant antibody cytokine fusion proteins
|
WO1992013069A1
(en)
*
|
1991-01-21 |
1992-08-06 |
Imperial College Of Science, Technology & Medicine |
Test and model for alzheimer's disease
|
US5912170A
(en)
*
|
1991-03-07 |
1999-06-15 |
The General Hospital Corporation |
Redirection of cellular immunity by protein-tyrosine kinase chimeras
|
US5851828A
(en)
*
|
1991-03-07 |
1998-12-22 |
The General Hospital Corporation |
Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
|
US6753162B1
(en)
|
1991-03-07 |
2004-06-22 |
The General Hospital Corporation |
Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
|
US6004811A
(en)
|
1991-03-07 |
1999-12-21 |
The Massachussetts General Hospital |
Redirection of cellular immunity by protein tyrosine kinase chimeras
|
US5843728A
(en)
*
|
1991-03-07 |
1998-12-01 |
The General Hospital Corporation |
Redirection of cellular immunity by receptor chimeras
|
US7049136B2
(en)
|
1991-03-07 |
2006-05-23 |
The General Hospital Corporation |
Redirection of cellular immunity by receptor chimeras
|
US7192584B2
(en)
|
1991-03-18 |
2007-03-20 |
Centocor, Inc. |
Methods of treating psoriasis with anti-TNF antibodies
|
CA2107553C
(en)
*
|
1991-04-05 |
2001-07-31 |
Nancy Lin |
Monoclonal antibodies to stem cell factor receptors
|
AU668349B2
(en)
|
1991-04-25 |
1996-05-02 |
Chugai Seiyaku Kabushiki Kaisha |
Reconstituted human antibody against human interleukin 6 receptor
|
DE69230545T2
(de)
*
|
1991-08-21 |
2000-07-06 |
Novartis Ag, Basel |
Antikörperderivate
|
AU669124B2
(en)
|
1991-09-18 |
1996-05-30 |
Kyowa Hakko Kirin Co., Ltd. |
Process for producing humanized chimera antibody
|
US6027725A
(en)
*
|
1991-11-25 |
2000-02-22 |
Enzon, Inc. |
Multivalent antigen-binding proteins
|
EP0571613B1
(de)
*
|
1991-12-13 |
2003-09-17 |
Xoma Corporation |
Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
|
US5869619A
(en)
*
|
1991-12-13 |
1999-02-09 |
Xoma Corporation |
Modified antibody variable domains
|
US8211422B2
(en)
|
1992-03-18 |
2012-07-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric receptor genes and cells transformed therewith
|
IL104570A0
(en)
|
1992-03-18 |
1993-05-13 |
Yeda Res & Dev |
Chimeric genes and cells transformed therewith
|
US5441870A
(en)
*
|
1992-04-15 |
1995-08-15 |
Athena Neurosciences, Inc. |
Methods for monitoring cellular processing of β-amyloid precursor protein
|
US5604102A
(en)
*
|
1992-04-15 |
1997-02-18 |
Athena Neurosciences, Inc. |
Methods of screening for β-amyloid peptide production inhibitors
|
US5851787A
(en)
*
|
1992-04-20 |
1998-12-22 |
The General Hospital Corporation |
Nucleic acid encoding amyloid precursor-like protein and uses thereof
|
US6610493B1
(en)
|
1993-06-17 |
2003-08-26 |
Brigham And Women's Hospital |
Screening compounds for the ability to alter the production of amyloid-β peptide
|
US6270766B1
(en)
|
1992-10-08 |
2001-08-07 |
The Kennedy Institute Of Rheumatology |
Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
|
US5605811A
(en)
*
|
1992-10-26 |
1997-02-25 |
Athena Neurosciences, Inc. |
Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein
|
AU5670194A
(en)
*
|
1992-11-20 |
1994-06-22 |
Enzon, Inc. |
Linker for linked fusion polypeptides
|
DE69419721T2
(de)
|
1993-01-12 |
2000-04-27 |
Biogen, Inc. |
Rekombinante anti-vla4 antikörpermoleküle
|
WO1994028025A1
(en)
|
1993-05-28 |
1994-12-08 |
The Scripps Research Institute |
Methods and compositions for inhibiting cd14 mediated cell activation
|
US5674493A
(en)
*
|
1993-08-31 |
1997-10-07 |
Thomas Jefferson University |
Compositions and methods for targeting cells with A2R and A2R monoclonal antibodies
|
WO1995008336A1
(en)
*
|
1993-09-22 |
1995-03-30 |
Nichols Institute Diagnostics |
Graves' ophthalmopathy associated antibodies, graves' ophthalmopathy orbital antigen, and methods of use thereof
|
DE69426571T2
(de)
|
1993-10-27 |
2001-08-09 |
Elan Pharm Inc |
TRANSGENE TIERE, DIE APP Allele mit der schwedischen Mutation beherbergen
|
CA2185162A1
(en)
|
1994-03-07 |
1995-09-14 |
Robert F. Halenback (Deceased) |
Compositions for the inhibition of tnf formation and uses thereof
|
US5874560A
(en)
|
1994-04-22 |
1999-02-23 |
The United States Of America As Represented By The Department Of Health And Human Services |
Melanoma antigens and their use in diagnostic and therapeutic methods
|
US6576236B1
(en)
|
1994-07-01 |
2003-06-10 |
Dana Farber Cancer Institute |
Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
|
US5614609A
(en)
*
|
1994-10-20 |
1997-03-25 |
Carlos F. Ibanez |
Serine threonine kinase receptor
|
EP1985703A3
(de)
|
1994-11-02 |
2009-04-08 |
Allelix Neuroscience, Inc. |
Spezifische Peripherie-Nervensystem-Natriumkanäle, DNS-Kodierung dafür, Kristallisierung, Röntgenstrahldiffraktion, Computermolekülformung, rationales Drogendesign, Drogenscreening und Verfahren zur Herstellung und Verwendung davon
|
IL114615A0
(en)
|
1995-07-16 |
1995-11-27 |
Yeda Res & Dev |
Modulators of the function of fas receptors and other proteins
|
US6091001A
(en)
*
|
1995-03-29 |
2000-07-18 |
Abgenix, Inc. |
Production of antibodies using Cre-mediated site-specific recombination
|
US6130364A
(en)
*
|
1995-03-29 |
2000-10-10 |
Abgenix, Inc. |
Production of antibodies using Cre-mediated site-specific recombination
|
US7175847B1
(en)
|
1995-06-07 |
2007-02-13 |
Biogen Idec Inc. |
Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
|
US6113898A
(en)
|
1995-06-07 |
2000-09-05 |
Idec Pharmaceuticals Corporation |
Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
|
US7153508B2
(en)
|
1995-06-07 |
2006-12-26 |
Biogen Idec Inc. |
Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
|
US6717031B2
(en)
|
1995-06-07 |
2004-04-06 |
Kate Dora Games |
Method for selecting a transgenic mouse model of alzheimer's disease
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
US6248555B1
(en)
|
1995-08-31 |
2001-06-19 |
The General Hospital Corporation |
Genetic alterations related to familial alzheimer's disease
|
JPH09124509A
(ja)
*
|
1995-10-27 |
1997-05-13 |
Sumitomo Electric Ind Ltd |
肝炎治療剤
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
US6015662A
(en)
*
|
1996-01-23 |
2000-01-18 |
Abbott Laboratories |
Reagents for use as calibrators and controls
|
US5714352A
(en)
*
|
1996-03-20 |
1998-02-03 |
Xenotech Incorporated |
Directed switch-mediated DNA recombination
|
AU720890B2
(en)
|
1996-05-31 |
2000-06-15 |
National American Red Cross, The |
Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids
|
US6716974B1
(en)
|
1996-05-31 |
2004-04-06 |
Maine Medical Center Research Institute |
Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids
|
CA2257357C
(en)
|
1996-06-07 |
2010-04-13 |
Neorx Corporation |
Humanized antibodies with modified glycosylation
|
EP0939810B1
(de)
|
1996-07-12 |
2007-02-07 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Transkriptions zwischen faktor-2 tif2
|
US7147851B1
(en)
|
1996-08-15 |
2006-12-12 |
Millennium Pharmaceuticals, Inc. |
Humanized immunoglobulin reactive with α4β7 integrin
|
ATE412740T1
(de)
|
1996-08-16 |
2008-11-15 |
Human Genome Sciences Inc |
Menschliches alpha-endokin
|
JP2001502895A
(ja)
*
|
1996-09-20 |
2001-03-06 |
ザ・ジェネラル・ホスピタル・コーポレイション |
アルファ―2―抗プラスミンに対するキメラ、ヒト化および一本鎖抗体
|
US7883872B2
(en)
|
1996-10-10 |
2011-02-08 |
Dyadic International (Usa), Inc. |
Construction of highly efficient cellulase compositions for enzymatic hydrolysis of cellulose
|
US5916771A
(en)
|
1996-10-11 |
1999-06-29 |
Abgenix, Inc. |
Production of a multimeric protein by cell fusion method
|
US6420140B1
(en)
|
1996-10-11 |
2002-07-16 |
Abgenix, Inc. |
Production of multimeric protein by cell fusion method
|
CA2665133A1
(en)
|
1996-10-25 |
1998-05-07 |
Human Genome Sciences, Inc. |
Neutrokine .alpha.
|
EP1780277A1
(de)
|
1997-01-15 |
2007-05-02 |
Yeda Research And Development Company, Ltd. |
IFN Rezeptor 1 bindende Proteine, dafür kodierende DNA und Verfahren zur Regulierung der zellulären Antwort auf Interferone
|
ATE426018T1
(de)
|
1997-04-10 |
2009-04-15 |
Stichting Katholieke Univ |
Pca3, pca3-gene und verfahren zu ihrer verwendung
|
US6054567A
(en)
|
1997-04-11 |
2000-04-25 |
The United States Of America As Represented By The Department Of Health And Human Services |
Recombinant proteins of a pakistani strain of hepatitis E and their use in diagnostic methods and vaccines
|
CA2288430C
(en)
|
1997-04-16 |
2013-04-09 |
Millennium Biotherapeutics, Inc. |
Crsp protein (cysteine-rich secreted proteins), nucleic acid molecules encoding them and uses therefor
|
US6204252B1
(en)
|
1997-04-25 |
2001-03-20 |
Aquila Biopharmaceuticals, Inc. |
Characterization of granulocytic ehrlichia and methods of use
|
AU7023798A
(en)
|
1997-04-30 |
1998-11-24 |
De Novo Enzyme Corporation |
Ricin-like toxin variants for treatment of cancer, viral or parasitic infections
|
ATE487737T1
(de)
|
1997-05-30 |
2010-11-15 |
Human Genome Sciences Inc |
32 humane sekretierte proteine
|
CA2206774A1
(en)
|
1997-06-16 |
1998-12-16 |
Rick E. Preddie |
"prionins", highly specific markers for noninvasive presymptomatic defection of tse diseases, and targets for therapeutic reagents to prevent and control tse diseases in animals and humans
|
EP2045322B1
(de)
|
1997-07-14 |
2015-07-01 |
Université de Liège |
Doppelmuskelbildung bei Säugetieren
|
US6103466A
(en)
*
|
1997-07-14 |
2000-08-15 |
University Of Liege |
Double-muscling in mammals
|
EP1015488B1
(de)
|
1997-09-17 |
2009-09-09 |
Human Genome Sciences, Inc. |
Interleukin-17 rezeptor-ähnliches protein
|
KR20010031713A
(ko)
|
1997-11-03 |
2001-04-16 |
벤슨 로버트 에이치. |
맥관형성 및 종양 성장 억제제인 맥관 내피 세포 성장억제제
|
CA2310892A1
(en)
|
1997-11-21 |
1999-06-03 |
Human Genome Sciences, Inc. |
Chemokine alpha-5
|
WO1999047538A1
(en)
|
1998-03-19 |
1999-09-23 |
Human Genome Sciences, Inc. |
Cytokine receptor common gamma chain like
|
GB9812545D0
(en)
|
1998-06-10 |
1998-08-05 |
Celltech Therapeutics Ltd |
Biological products
|
JP2000000097A
(ja)
|
1998-06-15 |
2000-01-07 |
Nippon Zoki Pharmaceut Co Ltd |
Nef結合蛋白質、該蛋白質をコードするDNA並びに該蛋白質に対するモノクローナル抗体
|
US6312689B1
(en)
|
1998-07-23 |
2001-11-06 |
Millennium Pharmaceuticals, Inc. |
Anti-CCR2 antibodies and methods of use therefor
|
EA005682B1
(ru)
|
1998-10-06 |
2005-04-28 |
Марк Аарон Эмалфарб |
Трансформированные грибы, в частности рода chrysosporium, способные к синтезу гетерологичных полипептидов
|
DE69839740D1
(de)
|
1998-10-22 |
2008-08-28 |
Univ Montana |
Vakzine enthaltend Omp85 Proteine von Neisseria gonorrhoeae und Neisseria meningitidis
|
PL350909A1
(en)
|
1999-02-12 |
2003-02-10 |
Genetics Inst |
Humanized immunoglobulin reactive with b7 molecules and methods of treatment therewith
|
US6972125B2
(en)
|
1999-02-12 |
2005-12-06 |
Genetics Institute, Llc |
Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
|
JP2002537769A
(ja)
|
1999-02-26 |
2002-11-12 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッド |
ヒトエンドカインαおよび使用方法
|
EP1179000A4
(de)
|
1999-02-26 |
2005-10-12 |
Millennium Pharm Inc |
Ausscheidungsproteine und ihre verwendung
|
DE19915057A1
(de)
|
1999-04-01 |
2000-10-19 |
Forschungszentrum Borstel |
Monoklonale Antikörper gegen das humane Mcm3 Protein, Verfahren zu ihrer Herstellung und ihre Verwendung
|
IL130225A0
(en)
|
1999-05-31 |
2000-06-01 |
Yissum Res Dev Co |
Novel uses of antibodies against ache and peptides thereof
|
US20040001826A1
(en)
|
1999-06-30 |
2004-01-01 |
Millennium Pharmaceuticals, Inc. |
Glycoprotein VI and uses thereof
|
US7291714B1
(en)
|
1999-06-30 |
2007-11-06 |
Millennium Pharmaceuticals, Inc. |
Glycoprotein VI and uses thereof
|
CA2379214A1
(en)
|
1999-07-27 |
2001-02-01 |
Unilever Plc |
Bleaching detergent compositions
|
CA2380331C
(en)
|
1999-08-09 |
2012-11-20 |
Lexigen Pharmaceuticals Corp. |
Multiple cytokine-antibody complexes
|
PT1210428E
(pt)
|
1999-08-23 |
2015-07-21 |
Genetics Inst Llc |
Pd-1, um recetor para b7-4 e suas utilizações
|
CA2381770C
(en)
|
1999-08-24 |
2007-08-07 |
Medarex, Inc. |
Human ctla-4 antibodies and their uses
|
US7368545B1
(en)
|
1999-09-29 |
2008-05-06 |
Diagnocure Inc. |
PCA3 messenger RNA species in benign and malignant prostate tissues
|
US7892541B1
(en)
|
1999-09-30 |
2011-02-22 |
Tumor Biology Investment Group, Inc. |
Soluble epidermal growth factor receptor isoforms
|
DK1234031T3
(en)
|
1999-11-30 |
2017-07-03 |
Mayo Foundation |
B7-H1, AN UNKNOWN IMMUNE REGULATORY MOLECULE
|
CA2897626C
(en)
|
2000-02-11 |
2020-03-24 |
Biogen Idec Ma Inc. |
Heterologous polypeptide of the tnf family
|
EP1276756A4
(de)
|
2000-04-12 |
2004-06-09 |
Human Genome Sciences Inc |
Albumin fusionsproteine
|
CA2399940A1
(en)
|
2000-04-13 |
2001-10-25 |
The Rockefeller University |
Enhancement of antibody-mediated immune responses
|
US20010046496A1
(en)
|
2000-04-14 |
2001-11-29 |
Brettman Lee R. |
Method of administering an antibody
|
US7632929B2
(en)
|
2000-04-20 |
2009-12-15 |
The Board Of Trustees Of The University Of Arkansas |
Methamphetamine-like hapten compounds, linkers, carriers and compositions and uses thereof
|
US7560534B2
(en)
|
2000-05-08 |
2009-07-14 |
Celldex Research Corporation |
Molecular conjugates comprising human monoclonal antibodies to dendritic cells
|
EP1714661A3
(de)
|
2000-05-19 |
2012-03-14 |
The Center for Blood Research, INC. |
Verfahren zur Diagnose und Behandlung von hämostatischen Störungen durch Modulation der P-Selectin Aktivität
|
GB0013810D0
(en)
|
2000-06-06 |
2000-07-26 |
Celltech Chiroscience Ltd |
Biological products
|
US20030031675A1
(en)
|
2000-06-06 |
2003-02-13 |
Mikesell Glen E. |
B7-related nucleic acids and polypeptides useful for immunomodulation
|
AU2001275378A1
(en)
|
2000-06-08 |
2001-12-17 |
The Center For Blood Research, Inc. |
Methods and compositions for inhibiting immunoglobulin-mediated reperfusion inj ury
|
WO2001096528A2
(en)
|
2000-06-15 |
2001-12-20 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor delta and epsilon
|
PT2281843T
(pt)
|
2000-06-16 |
2017-01-02 |
Human Genome Sciences Inc |
Anticorpos que se ligam imunoespecificamente a blys
|
US6803211B2
(en)
|
2000-08-25 |
2004-10-12 |
Pfizer Inc. |
Methods and compositions for diagnosing and treating disorders involving angiogenesis
|
EP1349946B1
(de)
|
2000-08-25 |
2011-01-26 |
BASF Plant Science GmbH |
Polynukleotide, die für prenylproteasen aus pflanzen kodieren
|
JP5113314B2
(ja)
|
2000-09-01 |
2013-01-09 |
ザ センター フォー ブラッド リサーチ インク |
所望のコンホメーションで安定させた改変ポリペプチド及び該ポリペプチドの作製方法
|
UA83458C2
(uk)
|
2000-09-18 |
2008-07-25 |
Байоджен Айдек Ма Інк. |
Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
|
EP1421174B1
(de)
|
2000-10-18 |
2009-12-23 |
The Brigham And Women's Hospital, Inc. |
E-selectin/l-selectin-liganden-polypeptide hämatopoetischer zellen und verfahren zu deren verwendung
|
US7858559B2
(en)
|
2000-11-17 |
2010-12-28 |
University Of Rochester |
In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
|
US6989247B2
(en)
|
2000-11-28 |
2006-01-24 |
Celltech R & D, Inc. |
Compositions and methods for diagnosing or treating psoriasis
|
BR0115715A
(pt)
|
2000-11-28 |
2004-02-03 |
Wyeth Corp |
Análise de expressão de ácidos nucleìcos e polipeptìdeos úteis na diagnose e tratamento de câncer da próstata
|
HUP0303905A3
(en)
|
2000-11-28 |
2005-11-28 |
Wyeth Corp |
Expression analysis of kiaa nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
|
WO2002046475A2
(en)
|
2000-12-08 |
2002-06-13 |
Curagen Corporation |
Method of detecting and treating tuberous sclerosis complex associated disorders
|
AU2002235761A1
(en)
|
2000-12-19 |
2002-07-01 |
Unilever Plc |
Stabilization of antibodies or fragments thereof
|
US7445802B2
(en)
|
2000-12-26 |
2008-11-04 |
Yeda Research And Development Co. Ltd |
Site-specific in situ generation of allicin using a targeted alliinase delivery system for the treatment of cancers, tumors, infectious diseases and other allicin-sensitive diseases
|
US20020132274A1
(en)
|
2001-01-17 |
2002-09-19 |
Nevalainen Marja T. |
Diagnostic and monitorings methods for cancer
|
WO2002068673A2
(en)
|
2001-02-23 |
2002-09-06 |
Dana-Farber Cancer Institute, Inc. |
Hin-1, a tumor suppressor gene
|
WO2002079415A2
(en)
|
2001-03-30 |
2002-10-10 |
Lexigen Pharmaceuticals Corp. |
Reducing the immunogenicity of fusion proteins
|
WO2002079499A1
(en)
|
2001-04-02 |
2002-10-10 |
Wyeth |
Pd-1, a receptor for b7-4, and uses therefor
|
US7384775B2
(en)
|
2001-04-16 |
2008-06-10 |
Wyeth |
Streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof
|
US7256257B2
(en)
|
2001-04-30 |
2007-08-14 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
US7744882B2
(en)
|
2001-05-31 |
2010-06-29 |
Tumor Biology Investment Group, Inc. |
Soluble ErbB3 methods of detection and antibodies
|
US7745398B2
(en)
|
2001-05-31 |
2010-06-29 |
Tumor Biology Investment Group, Inc. |
Soluble ErbB3 and treatment of cancer
|
JP4619651B2
(ja)
|
2001-06-01 |
2011-01-26 |
コーネル・リサーチ・ファンデーション・インコーポレイテッド |
前立腺特異的膜抗原に対する修飾抗体およびその使用
|
US7514078B2
(en)
|
2001-06-01 |
2009-04-07 |
Cornell Research Foundation, Inc. |
Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
|
DE60233509D1
(de)
|
2001-06-20 |
2009-10-08 |
Fibron Ltd |
Fgfr3 blockierende antikörper, verfahren zum screening darauf und verwendungen davon
|
US20040142325A1
(en)
|
2001-09-14 |
2004-07-22 |
Liat Mintz |
Methods and systems for annotating biomolecular sequences
|
EP3187592B1
(de)
|
2001-09-20 |
2018-12-12 |
Immunex Corporation |
Auswahl von heteromeren polypeptide exprimierenden zellen
|
CA2460916A1
(en)
|
2001-10-04 |
2003-04-10 |
Laura Carter |
Methods and compositions for modulating interleukin-21 receptor activity
|
MX339524B
(es)
|
2001-10-11 |
2016-05-30 |
Wyeth Corp |
Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
|
DE10151511A1
(de)
|
2001-10-18 |
2003-05-08 |
Basf Lynx Bioscience Ag |
ee3-Proteinfamilie und zugrundeliegende DNA-Sequenzen
|
EP1944043A1
(de)
|
2001-11-21 |
2008-07-16 |
The Trustees of the University of Pennsylvania |
Nukleinsäure- und Aminosäuresequenzen von Affen-Adenoviren, hergeleitete Vektoren und Verwendungsverfahren.
|
CA2468733C
(en)
|
2001-11-30 |
2013-06-11 |
Biogen Idec Ma Inc. |
Antibodies against monocyte chemotactic proteins
|
GB0129105D0
(en)
|
2001-12-05 |
2002-01-23 |
Celltech R&D Ltd |
Expression control using variable intergenic sequences
|
WO2003049673A2
(en)
|
2001-12-05 |
2003-06-19 |
Baylor College Of Medicine |
Methods and compositions for control of bone formation via modulation of sympathetic tone
|
ES2337989T3
(es)
|
2001-12-18 |
2010-05-03 |
Endocube Sas |
Nuevas proteinas asociadas a la muerte de la familia thap y rutas par4 relacionadas implicadas en el control de la apoptosis.
|
US7858297B2
(en)
|
2001-12-18 |
2010-12-28 |
Centre National De La Recherche Scientifique Cnrs |
Chemokine-binding protein and methods of use
|
EP1463807A4
(de)
|
2001-12-19 |
2006-04-12 |
Bristol Myers Squibb Co |
Formiatdehydrogenase aus pichia pastoris und verwendungen dafür
|
JP2005526233A
(ja)
|
2001-12-31 |
2005-09-02 |
ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド |
乳房上皮細胞によるソライアシン発現を用いた方法
|
EP2292247A3
(de)
|
2002-03-05 |
2011-10-05 |
Ramot at Tel Aviv University Ltd. |
Immunisierende zusammensetzung und verfahren zur auslösung einer immunantwort gegen die beta-secretase-cleavage-stelle von amyloid-vorläuferprotein
|
GB0207533D0
(en)
|
2002-04-02 |
2002-05-08 |
Oxford Glycosciences Uk Ltd |
Protein
|
JP2005535572A
(ja)
|
2002-04-12 |
2005-11-24 |
メディミューン,インコーポレーテッド |
組換え抗インターロイキン−9抗体
|
JP2006511194A
(ja)
|
2002-05-02 |
2006-04-06 |
デイビッド ラブジョイ |
テネウリンc末端関連ペプチド(tcap)並びにこれらに関連する方法および使用
|
WO2003097798A2
(en)
|
2002-05-14 |
2003-11-27 |
Martek Biosciences Corporation |
Carotene synthase gene and uses therefor
|
AU2003240790A1
(en)
|
2002-05-28 |
2003-12-12 |
Pharmacia Corporation |
Antibody peg positional isomers, compositions comprising same, and use thereof
|
JP4643255B2
(ja)
|
2002-06-10 |
2011-03-02 |
バクシネックス インコーポレーティッド |
乳癌および膀胱癌において差次的に発現される遺伝子ならびにコードされるポリペプチド
|
WO2003106656A2
(en)
|
2002-06-17 |
2003-12-24 |
Thrasos, Inc. |
Single domain tdf-related compounds and analogs thereof
|
US7250551B2
(en)
|
2002-07-24 |
2007-07-31 |
President And Fellows Of Harvard College |
Transgenic mice expressing inducible human p25
|
DK1545613T3
(da)
|
2002-07-31 |
2011-11-14 |
Seattle Genetics Inc |
Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
|
AR040778A1
(es)
|
2002-08-06 |
2005-04-20 |
Glaxo Group Ltd |
Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
|
EP2181595A1
(de)
|
2002-08-16 |
2010-05-05 |
Yeda Research And Development Company Ltd. |
Tumorassoziiertes Antigen, Peptide davon, und deren Verwendung als Antitumorimpfstoffe
|
EP2311978A1
(de)
|
2002-08-20 |
2011-04-20 |
Millennium Pharmaceuticals, Inc. |
Zusammensetzungen, Kits und Verfahren zur Identifizierung, Beurteilung, Vorbeugung und Therapie von Gebärmutterhalskrebs
|
US7785608B2
(en)
|
2002-08-30 |
2010-08-31 |
Wyeth Holdings Corporation |
Immunogenic compositions for the prevention and treatment of meningococcal disease
|
US7563771B2
(en)
|
2002-11-13 |
2009-07-21 |
Uab Research Foundation |
Synthetic single domain polypeptides mimicking apolipoprotein E
|
EP2112229A3
(de)
|
2002-11-25 |
2009-12-02 |
Sequenom, Inc. |
Verfahren zum Identifizieren des Brustkrebsrisikos und zugehörige Behandlungen
|
EP1581629B1
(de)
|
2002-12-06 |
2015-04-01 |
Millennium Pharmaceuticals, Inc. |
Verfahren zur identifizierung,beurteilung und behandlung von patienten mit einer proteasomen inhibitions therapie
|
PT2311848E
(pt)
|
2002-12-23 |
2013-10-03 |
Vical Inc |
Vacinas à base de polinucleótido optimizadas por codão contra a infecção do citomegalovírus humano
|
US8557957B2
(en)
|
2003-01-03 |
2013-10-15 |
Elizabeth Kornecki |
Methods of treating disorders by administration of F11 receptor antagonists
|
US20050265992A1
(en)
|
2003-01-03 |
2005-12-01 |
The Research Foundation Of State University Of New York |
F11 receptor (F11R) antagonists as therapeutic agents
|
US8206931B2
(en)
|
2003-01-17 |
2012-06-26 |
The Johns Hopkins University |
Methods of identifying modulators of cellular glycosylation using GTRAP3-18
|
ATE552860T1
(de)
|
2003-01-31 |
2012-04-15 |
Celldex Res Corp |
Antikörper-vakzine-konjugate und ihre verwendungen
|
US9259459B2
(en)
|
2003-01-31 |
2016-02-16 |
Celldex Therapeutics Inc. |
Antibody vaccine conjugates and uses therefor
|
ES2427853T3
(es)
|
2003-02-07 |
2013-11-04 |
Diagnocure Inc. |
Procedimiento para detectar cáncer de próstata en una muestra
|
GB0303337D0
(en)
|
2003-02-13 |
2003-03-19 |
Celltech R&D Ltd |
Biological products
|
US20040180387A1
(en)
|
2003-03-13 |
2004-09-16 |
Fujirebio Diagnostics, Inc. |
Detection of urinary mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of ovarian cancer
|
SE0301087D0
(sv)
|
2003-04-14 |
2003-04-14 |
Cartela Ab |
New monoclonal antibody
|
GB0309126D0
(en)
|
2003-04-17 |
2003-05-28 |
Neutec Pharma Plc |
Clostridium difficile focussed antibodies
|
EP2829283B1
(de)
|
2003-04-30 |
2017-06-07 |
Universität Zürich |
Verfahren zur Behandlung von Krebs unter Verwendung eines Immuntoxins
|
PT2374819T
(pt)
|
2003-05-12 |
2017-07-04 |
Helion Biotech Aps |
Anticorpos para masp-2
|
US20050014932A1
(en)
|
2003-05-15 |
2005-01-20 |
Iogenetics, Llc |
Targeted biocides
|
US8080642B2
(en)
|
2003-05-16 |
2011-12-20 |
Vical Incorporated |
Severe acute respiratory syndrome DNA compositions and methods of use
|
US7892563B2
(en)
|
2003-05-20 |
2011-02-22 |
Wyeth Holdings Corporation |
Methods for treatment of severe acute respiratory syndrome (SARS)
|
EP1635763B1
(de)
|
2003-06-09 |
2012-08-08 |
Alnylam Pharmaceuticals Inc. |
Verfahren zur behandlung von neurodegenerativen erkrankungen
|
US7871768B2
(en)
|
2003-08-04 |
2011-01-18 |
The Hospital For Sick Children |
Lafora's disease gene
|
IL158287A0
(en)
|
2003-10-07 |
2004-05-12 |
Yeda Res & Dev |
Antibodies to nik, their preparation and use
|
MXPA06003402A
(es)
|
2003-10-07 |
2006-06-27 |
Millennium Pharm Inc |
Moleculas de acidos nucleicos y proteinas para la identificacion, evaluacion, prevencion y tratamiento de cancer de ovario.
|
KR101520209B1
(ko)
|
2003-11-06 |
2015-05-13 |
시애틀 지네틱스, 인크. |
리간드에 접합될 수 있는 모노메틸발린 화합물
|
WO2005047475A2
(en)
|
2003-11-11 |
2005-05-26 |
Regents Of The University Of Minnesota |
Regulation of cell membrane-mediated effects
|
JP4833850B2
(ja)
|
2003-11-21 |
2011-12-07 |
ユセベ ファルマ ソシエテ アノニム |
Il−17活性阻害による多発性硬化症を治療するための方法
|
EP1631311A4
(de)
|
2003-12-10 |
2007-04-11 |
Millennium Pharm Inc |
Humanisierte anti-ccr2-antikörper und anwendungsverfahren
|
CA2494572A1
(en)
|
2003-12-19 |
2005-06-19 |
Cytochroma Inc. |
Cytochrome p450 24 (cyp24) monoclonal antibody and methods and uses thereof
|
WO2005063992A1
(ja)
|
2003-12-30 |
2005-07-14 |
Suntory Limited |
新規血清型のストレプトコッカス ミュータンスおよびその利用
|
TR201815885T4
(tr)
|
2004-01-07 |
2018-11-21 |
Novartis Vaccines & Diagnostics Inc |
M-csf spesifik monoklonal antikorlar ve bunların kullanımı.
|
EP2444805A3
(de)
|
2004-01-21 |
2012-06-20 |
Fujirebio America, Inc. |
Erkennung von Mesothelin-/Megakaryozyten zur Potenzierung von faktorbezogenen Peptiden in peritonealer Flüssigkeit zur Bewertung des Peritoneum und Peritonealhöhle
|
AU2005206277B2
(en)
|
2004-01-22 |
2011-06-23 |
Merck Patent Gmbh |
Anti-cancer antibodies with reduced complement fixation
|
AU2005235811B2
(en)
|
2004-02-06 |
2011-11-03 |
Morphosys Ag |
Anti-CD38 human antibodies and uses therefor
|
KR20120083534A
(ko)
|
2004-02-06 |
2012-07-25 |
메다렉스, 인코포레이티드 |
클로스트리듐 디피실리 독소에 대한 항체 및 이의 용도
|
PL1713503T3
(pl)
|
2004-02-10 |
2014-02-28 |
Univ Colorado Regents |
Hamowanie czynnika B, alternatywny szlak dopełniacza i związane z tym sposoby
|
EP2290077B1
(de)
|
2004-03-01 |
2016-01-27 |
Immune Disease Institute, Inc. |
Natürliche IgM-Antikörper und Inhibitoren
|
AU2005224081B2
(en)
|
2004-03-12 |
2011-06-30 |
Vasgene Therapeutics, Inc. |
Polypeptide compounds for inhibiting angiogenesis and tumor growth
|
CA2560742A1
(en)
|
2004-03-23 |
2005-10-06 |
Biogen Idec Ma Inc. |
Receptor coupling agents and therapeutic uses thereof
|
US7794713B2
(en)
|
2004-04-07 |
2010-09-14 |
Lpath, Inc. |
Compositions and methods for the treatment and prevention of hyperproliferative diseases
|
ES2442386T3
(es)
|
2004-04-23 |
2014-02-11 |
Bundesrepublik Deutschland Letztvertreten Durch Das Robert Koch-Institut Vertreten Durch Seinen Pr |
Método para el tratamiento de condiciones mediadas por células T por la disminución de las células positivas de ICOS in vivo.
|
JP4836942B2
(ja)
|
2004-04-30 |
2011-12-14 |
コーセラ, インコーポレイテッド |
リラキシンの調節による胎仔の発育の制御のための方法および組成物
|
EP1598428A1
(de)
|
2004-05-18 |
2005-11-23 |
Georg Dewald |
Verfahren und Kits zum Nachweis von erblichen angioedema typ III
|
AU2005248361B2
(en)
|
2004-05-18 |
2010-03-11 |
Vical Incorporated |
Influenza virus vaccine composition and methods of use
|
WO2005115992A1
(en)
|
2004-05-23 |
2005-12-08 |
Housey Pharmaceuticals, Inc. |
Theramutein modulators
|
KR100620554B1
(ko)
|
2004-06-05 |
2006-09-06 |
한국생명공학연구원 |
Tag-72에 대한 인간화 항체
|
EP2319526A1
(de)
|
2004-06-17 |
2011-05-11 |
Thrasos Therapeutics, Inc. |
TDF-ähnliche Verbindungen und deren Analogal
|
GB0414054D0
(en)
|
2004-06-23 |
2004-07-28 |
Owen Mumford Ltd |
Improvements relating to automatic injection devices
|
US7973134B2
(en)
|
2004-07-07 |
2011-07-05 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways
|
EP2287310B1
(de)
|
2004-07-22 |
2015-05-06 |
Five Prime Therapeutics, Inc. |
Zusammensetzungen und Verfahren zur Verwendung von MGD-CSF zur Krankheitsbehandlung
|
US7335491B2
(en)
|
2004-08-27 |
2008-02-26 |
Wyeth Research Ireland Limited |
Production of anti-abeta
|
US7294484B2
(en)
|
2004-08-27 |
2007-11-13 |
Wyeth Research Ireland Limited |
Production of polypeptides
|
TWI364458B
(en)
|
2004-08-27 |
2012-05-21 |
Wyeth Res Ireland Ltd |
Production of tnfr-lg
|
US7935790B2
(en)
|
2004-10-04 |
2011-05-03 |
Cell Singaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways
|
PL1810026T3
(pl)
|
2004-10-06 |
2018-08-31 |
Mayo Foundation For Medical Education And Research |
B7-H1 i PD-1 w leczeniu raka nerkowokomórkowego
|
NZ554520A
(en)
|
2004-10-22 |
2010-03-26 |
Amgen Inc |
Methods for refolding of recombinant antibodies
|
AU2005332660A1
(en)
|
2004-11-12 |
2006-12-14 |
Seattle Genetics, Inc. |
Auristatins having an aminobenzoic acid unit at the N terminus
|
US7807789B2
(en)
|
2004-12-21 |
2010-10-05 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
|
CA2491067A1
(en)
|
2004-12-24 |
2006-06-24 |
Stichting Katholieke Universiteit |
Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer
|
GT200600031A
(es)
|
2005-01-28 |
2006-08-29 |
|
Formulacion anticuerpo anti a beta
|
JP2008532493A
(ja)
|
2005-02-14 |
2008-08-21 |
ワイス |
Il−17fとil−17rとの間の相互作用の特性解析
|
EP1695981A1
(de)
|
2005-02-25 |
2006-08-30 |
Forschungsverbund Berlin e.V. |
Verfahren zum Redox-Potential-abhängigen Nachweis von Targetmolekülen durch wechselwirkende Polypeptide
|
US7829673B2
(en)
|
2005-03-23 |
2010-11-09 |
Genmab A/S |
Antibodies against CD38 for treatment of multiple myeloma
|
GT200600148A
(es)
|
2005-04-14 |
2006-11-22 |
|
Metodos para el tratamiento y la prevencion de fibrosis
|
AU2006236225C1
(en)
|
2005-04-19 |
2013-05-02 |
Seagen Inc. |
Humanized anti-CD70 binding agents and uses thereof
|
WO2006117782A2
(en)
|
2005-05-04 |
2006-11-09 |
Quark Pharmaceuticals, Inc. |
Recombinant antibodies against cd55 and cd59 and uses thereof
|
WO2006125076A2
(en)
|
2005-05-18 |
2006-11-23 |
Trinity Biosystems, Inc. |
Methods and compositions for immunizing against chlamydia infection
|
US8431110B2
(en)
|
2005-05-23 |
2013-04-30 |
Hmi Medical Innovations, Llc. |
Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators
|
BRPI0618160A2
(pt)
|
2005-05-26 |
2011-08-16 |
Univ Colorado |
inibição da via alternativa complemento para tratamento de danos cerebrais traumáticos, danos na medula espinhal e condições relacionadas
|
CA2608504A1
(en)
|
2005-05-31 |
2006-12-07 |
Duska Scientific Co. |
Inhibition of neuronal damage
|
EP2364998A1
(de)
|
2005-06-16 |
2011-09-14 |
The Feinstein Institute for Medical Research |
Antikörper gegen HMGB1 und Fragmente davon
|
EP1896504B1
(de)
|
2005-06-17 |
2012-11-21 |
Wyeth LLC |
VERFAHREN ZUR REINIGUNG FC-REGIONSHALTIGER ANTIKöRPER
|
SI2314623T1
(sl)
|
2005-06-21 |
2012-11-30 |
Xoma Technology Ltd |
IL beta vezavna protitelesa in njihovi fragmenti
|
EP2722051B1
(de)
|
2005-07-07 |
2018-11-07 |
Seattle Genetics, Inc. |
Monomethylvalinverbindungen mit Phenylalaninseitenkettenmodifikationen am C-Terminus
|
CA2616005C
(en)
|
2005-07-18 |
2015-09-22 |
Seattle Genetics, Inc. |
Beta-glucuronide-linker drug conjugates
|
SG164379A1
(en)
|
2005-07-21 |
2010-09-29 |
Genmab As |
Potency assays for antibody drug substance binding to an fc receptor
|
EP1913027B1
(de)
|
2005-07-28 |
2015-03-04 |
Novartis AG |
M-csf-spezifische monoklonale antikörper und anwendungen davon
|
EP1934867A2
(de)
|
2005-08-31 |
2008-06-25 |
Cell Signaling Technology, Inc. |
Reagentien zum nachweis der proteinphosphorylierung in leukämie-signalwegen
|
WO2007035872A2
(en)
|
2005-09-20 |
2007-03-29 |
Thrasos Therapeutics, Inc. |
Tdf-related compounds and analogs thereof
|
DE602006021768D1
(de)
|
2005-09-28 |
2011-06-16 |
Dickinson & Co |
Nachweis von lysophosphatidylcholin für die prognose oder diagnose eines systemischen entzündungszustands
|
UA92504C2
(en)
|
2005-10-12 |
2010-11-10 |
Эли Лилли Энд Компани |
Anti-myostatin monoclonal antibody
|
EP2860192B1
(de)
|
2005-10-12 |
2017-09-27 |
MorphoSys AG |
Gewinnung und Profilierung von vollständig humanen, von HuCAL GOLD-abgeleiteten therapeutischen Antikörpern für humanes CD38
|
US8597646B2
(en)
|
2005-10-25 |
2013-12-03 |
The Johns Hopkins University |
Methods and compositons featuring TGF-beta antagonists for the treatment of marfan syndrome and associated disorders
|
CA2626804A1
(en)
|
2005-11-01 |
2007-08-09 |
Abbott Biotechnology Ltd. |
Methods and compositions for diagnosing ankylosing spondylitis using biomarkers
|
WO2007055916A2
(en)
|
2005-11-07 |
2007-05-18 |
The Rockefeller University |
Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
|
EA014900B1
(ru)
|
2005-11-07 |
2011-02-28 |
Зе Скрипс Ресеч Инститьют |
Композиции и способы контроля специфичности передачи сигналов, опосредуемой тканевым фактором
|
JP5415767B2
(ja)
|
2005-11-10 |
2014-02-12 |
ボード オブ スーパーバイザーズ オブ ルイジアナ ステイト ユニバーシティー アンド アグリカルチュラル アンド メカニカル カレッジ |
依存症及び他の精神神経疾患の治療のための組成物及び方法
|
EP1949109B1
(de)
|
2005-11-14 |
2012-02-29 |
MetaMol Theranostics, LLC |
Tumorinvasionsfördernde peptidsequenz
|
EP2336181A1
(de)
|
2005-12-09 |
2011-06-22 |
UCB Pharma, S.A. |
Antikörpermoleküle mit menschlicher IL-6-Spezifizität
|
EP3366702B1
(de)
|
2005-12-13 |
2023-08-09 |
Eli Lilly And Company |
Anti-il-17-antikörper
|
US20070264687A1
(en)
|
2005-12-15 |
2007-11-15 |
Min-Yuan Chou |
Recombinant triplex scaffold-based polypeptides
|
US10183986B2
(en)
|
2005-12-15 |
2019-01-22 |
Industrial Technology Research Institute |
Trimeric collagen scaffold antibodies
|
GB0525662D0
(en)
|
2005-12-16 |
2006-01-25 |
Glaxo Group Ltd |
Immunoglobulins
|
DK1991273T4
(da)
|
2006-02-10 |
2022-02-07 |
Life Technologies Corp |
Mærkning og påvisning af post-translationelt modificerede proteiner
|
TW200744634A
(en)
|
2006-02-21 |
2007-12-16 |
Wyeth Corp |
Methods of using antibodies against human IL-22
|
TWI417301B
(zh)
|
2006-02-21 |
2013-12-01 |
Wyeth Corp |
對抗人類介白素-22(il-22)之抗體及其用途
|
AU2007225044C1
(en)
|
2006-03-15 |
2018-03-29 |
Alexion Pharmaceuticals, Inc. |
Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
|
EP1854477B9
(de)
|
2006-03-16 |
2018-03-14 |
Dyax Corp. |
Peptid-Inhibitoren von Plasma Kallikrein zur Verwendung in der Behandlung von Augenerkrankungen
|
JP2009532358A
(ja)
|
2006-03-31 |
2009-09-10 |
マサチューセッツ・インスティテュート・オブ・テクノロジー |
突然変異型egf受容体を発現する腫瘍の治療
|
KR20140071452A
(ko)
|
2006-04-05 |
2014-06-11 |
애브비 바이오테크놀로지 리미티드 |
항체 정제
|
EP2007426A4
(de)
|
2006-04-10 |
2010-06-16 |
Abbott Biotech Ltd |
Anwendungen und zusammensetzungen zur behandlung von psoriasis-arthritis
|
EP2666479A3
(de)
|
2006-04-10 |
2014-03-26 |
Abbott Biotechnology Ltd |
Anwendungen und Zusammensetzungen zur Behandlung von juveniler rheumatoider Arthritis
|
CA2564435A1
(en)
|
2006-04-10 |
2007-10-10 |
Abbott Biotechnology Ltd. |
Methods for monitoring and treating intestinal disorders
|
WO2007124133A2
(en)
|
2006-04-20 |
2007-11-01 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine Incorporated |
Methods and compositions based on shiga toxin type 1 protein
|
AU2007249698A1
(en)
|
2006-05-15 |
2007-11-22 |
University Of Kentucky |
Toll-like receptor (TLR) stimulation for ocular angiogenesis and macular degeneration
|
US9274129B2
(en)
|
2006-05-31 |
2016-03-01 |
Lpath, Inc. |
Methods and reagents for detecting bioactive lipids
|
US9274130B2
(en)
|
2006-05-31 |
2016-03-01 |
Lpath, Inc. |
Prevention and treatment of pain using antibodies to lysophosphatidic acid
|
US8796429B2
(en)
|
2006-05-31 |
2014-08-05 |
Lpath, Inc. |
Bioactive lipid derivatives, and methods of making and using same
|
US7862812B2
(en)
|
2006-05-31 |
2011-01-04 |
Lpath, Inc. |
Methods for decreasing immune response and treating immune conditions
|
US20080138334A1
(en)
|
2006-05-31 |
2008-06-12 |
Sabbadini Roger A |
Immune-Derived Moieties Reactive Against Bioactive Lipids, and Methods of Making and Using Same
|
EP2035439A4
(de)
|
2006-06-05 |
2010-01-13 |
Cancer Care Ontario |
Abschätzung des risikos von colorectalkrebs
|
GB0611116D0
(en)
|
2006-06-06 |
2006-07-19 |
Oxford Genome Sciences Uk Ltd |
Proteins
|
ES2415655T3
(es)
|
2006-06-15 |
2013-07-26 |
The Board Of Trustees Of The University Of Arkansas |
Anticuerpos monoclonales que reconocen selectivamente Metanfetamina y compuestos similares a Metanfetamina
|
WO2007144893A2
(en)
|
2006-06-15 |
2007-12-21 |
Fibron Ltd. |
Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
|
AU2007264672B2
(en)
|
2006-06-28 |
2013-03-14 |
Hadasit Medical Research Services & Development Ltd |
Caspase-8 and inflammation, infection and wound healing
|
TWI527603B
(zh)
|
2006-06-30 |
2016-04-01 |
艾伯維生物技術有限責任公司 |
自動注射裝置
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
WO2008003319A1
(en)
|
2006-07-04 |
2008-01-10 |
Genmab A/S |
Cd20 binding molecules for the treatment of copd
|
WO2008003515A1
(en)
|
2006-07-07 |
2008-01-10 |
Intercell Ag |
Small streptococcus pyogenes antigens and their use
|
DK3255141T3
(da)
|
2006-07-13 |
2022-01-31 |
Wyeth Llc |
Fremstilling af antistoffer med forbedret glycosyleringsmønster
|
EP2420252A1
(de)
|
2006-08-04 |
2012-02-22 |
Novartis AG |
EPHB3-spezifischer Antikörper und Verwendungen davon
|
US7939636B2
(en)
|
2006-08-11 |
2011-05-10 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in c-Src signaling pathways
|
CA2661023C
(en)
|
2006-08-18 |
2017-08-15 |
Novartis Ag |
Prlr-specific antibody and uses thereof
|
US20090203602A1
(en)
|
2006-09-01 |
2009-08-13 |
Cohava Gelber |
Compositions and methods for diagnosis and treatment of type 2 diabetes
|
US7951776B2
(en)
|
2006-09-01 |
2011-05-31 |
American Type Culture Collection |
Methods for treatment of type 1 diabetes
|
EP2913342A1
(de)
|
2006-09-05 |
2015-09-02 |
Alexion Pharmaceuticals, Inc. |
Zusammensetzungen zur behandlung von antikörpervermittelten neuropathien
|
BRPI0716762A2
(pt)
|
2006-09-13 |
2013-09-24 |
Abbott Lab |
melhorias da cultura celular
|
EP2500416A1
(de)
|
2006-09-13 |
2012-09-19 |
Abbott Laboratories |
Verbesserungen an Zellkulturen
|
SI2081595T1
(sl)
|
2006-09-26 |
2019-10-30 |
Genmab As |
Anti-cd38 plus kortikosteroidi plus ne-kortikosteroidni kemoterapevtik za zdravljenje tumorjev
|
US20120282245A1
(en)
|
2006-10-03 |
2012-11-08 |
Biogen Idec Ma Inc. |
Biomarkers and assays for the treatment of cancer
|
BRPI0719250A2
(pt)
|
2006-10-12 |
2015-06-16 |
Wyeth Corp |
Métodos e composições com opalescência reduzida.
|
GB0620729D0
(en)
|
2006-10-18 |
2006-11-29 |
Ucb Sa |
Biological products
|
RU2460541C2
(ru)
|
2006-10-27 |
2012-09-10 |
Лпат, Инк. |
Композиции и способы связывания сфингозин-1-фосфата
|
CA2667706A1
(en)
|
2006-10-27 |
2008-05-08 |
Lpath, Inc. |
Compositions and methods for treating ocular diseases and conditions
|
WO2008055260A2
(en)
|
2006-11-03 |
2008-05-08 |
Wyeth |
Glycolysis-inhibiting substances in cell culture
|
US20110294782A1
(en)
|
2006-11-10 |
2011-12-01 |
Massachusetts Institute Of Technology |
Small molecule pak inhibitors
|
JP2010510235A
(ja)
|
2006-11-15 |
2010-04-02 |
ファンクショナル・ジェネティクス・インコーポレーテッド |
抗tsg101抗体およびウイルス感染の処置のためのその使用
|
WO2008070593A2
(en)
|
2006-12-01 |
2008-06-12 |
Seattle Genetics, Inc. |
Variant target binding agents and uses thereof
|
EA200900767A1
(ru)
|
2006-12-07 |
2009-12-30 |
Новартис Аг |
Антагонистические антитела против ephb3
|
JP2010512324A
(ja)
|
2006-12-08 |
2010-04-22 |
アッテヌオン エル エル シー |
ウロキナーゼ型プラスミノーゲン活性化因子受容体エピトープ、それに由来するモノクローナル抗体及びそれらの使用方法
|
EP2505651A3
(de)
|
2006-12-10 |
2013-01-09 |
Dyadic International, Inc. |
Pilzisolate mit reduzierter Proteaseaktivität
|
US7695718B2
(en)
|
2006-12-20 |
2010-04-13 |
Xoma Technology Ltd. |
Methods for the treatment of IL-1β related diseases
|
AR064642A1
(es)
|
2006-12-22 |
2009-04-15 |
Wyeth Corp |
Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
|
JP5694668B2
(ja)
|
2006-12-29 |
2015-04-01 |
ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレイトTHE REGENTS OF THE UNIVERSITY OF COLORADO,a body corporate |
自己免疫疾患の診断上および治療上の標的ならびにその用途
|
EP2115173B1
(de)
|
2007-01-08 |
2011-09-21 |
Government of the USA, as Represented by the Secretary, Department of Health and Human Services |
Slco1b3-genotyp
|
US8343510B2
(en)
|
2007-01-12 |
2013-01-01 |
Intercell Ag |
Protective proteins of S. agalactiae, combinations thereof and methods of using the same
|
ATE526017T1
(de)
|
2007-01-22 |
2011-10-15 |
Genentech Inc |
Abscheidung von polyelektrolyten und reinigung von antikörpern
|
WO2008098139A2
(en)
|
2007-02-07 |
2008-08-14 |
The Regents Of The University Of Colorado |
Axl tyrosine kinase inhibitors and methods of making and using the same
|
JP5662684B2
(ja)
|
2007-02-16 |
2015-02-04 |
ジェンザイム コーポレーション |
甲状腺障害リスクの同定方法
|
WO2008104803A2
(en)
|
2007-02-26 |
2008-09-04 |
Oxford Genome Sciences (Uk) Limited |
Proteins
|
EP3118221B1
(de)
|
2007-02-26 |
2019-08-21 |
Oxford BioTherapeutics Ltd |
Proteine
|
PT2115126E
(pt)
|
2007-03-02 |
2015-08-24 |
Wyeth Llc |
Utilização de cobre e glutamato na cultura de células para a produção de polipeptídeos
|
WO2008106785A1
(en)
|
2007-03-05 |
2008-09-12 |
Cancer Care Ontario |
Assessment of risk for colorectal cancer
|
US20090081659A1
(en)
|
2007-03-07 |
2009-03-26 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
|
EP1975184A3
(de)
|
2007-03-26 |
2008-11-26 |
Cell Signaling Technology, Inc. |
Serin- oder Threonin-Phosphorylationsorte
|
EP1983003A3
(de)
|
2007-04-19 |
2009-03-11 |
Peter Hornbeck |
Tyrosinphosphorylationsstellen und spezifische Antikörper
|
US7977462B2
(en)
|
2007-04-19 |
2011-07-12 |
Cell Signaling Technology, Inc. |
Tyrosine phosphorylation sites
|
EP1983002A3
(de)
|
2007-04-19 |
2009-03-11 |
Peter Hornbeck |
Tyrosinphosphorylations-Stellen und spezifische Antikörper
|
WO2008131216A1
(en)
|
2007-04-20 |
2008-10-30 |
The Board Of Trustees Of The University Of Arkansas |
Hapten compounds and compositions and uses thereof
|
US20090053831A1
(en)
|
2007-05-01 |
2009-02-26 |
Cell Signaling Technology, Inc. |
Tyrosine phosphorylation sites
|
AU2008248755A1
(en)
|
2007-05-02 |
2008-11-13 |
Intercell Ag |
Klebsiella antigens
|
WO2008143797A1
(en)
|
2007-05-11 |
2008-11-27 |
Genzyme Corporation |
Methods of producing a secreted protein
|
US9163091B2
(en)
|
2007-05-30 |
2015-10-20 |
Lpath, Inc. |
Compositions and methods for binding lysophosphatidic acid
|
EP2164992B1
(de)
|
2007-05-30 |
2016-05-04 |
Lpath, Inc. |
Zusammensetzungen und verfahren zur bindung von lysophosphatidinsäure
|
CA2688275A1
(en)
|
2007-05-31 |
2008-12-04 |
Genmab A/S |
Stable igg4 antibodies
|
WO2008154543A2
(en)
|
2007-06-11 |
2008-12-18 |
Abbott Biotechnology Ltd. |
Methods for treating juvenile idiopathic arthritis
|
US20080317768A1
(en)
|
2007-06-21 |
2008-12-25 |
Boeing Company |
Bioconjugated nanoparticles
|
WO2009020632A1
(en)
|
2007-08-06 |
2009-02-12 |
Burnham Institute For Medical Research |
Znf206: a novel regulator of embryonic stem cell self-renewal and pluripotency
|
JP5749009B2
(ja)
|
2007-08-13 |
2015-07-15 |
バスジーン セラピューティクス,インコーポレイテッドVasgenetherapeutics,Inc. |
EphB4に結合するヒト化抗体を利用する癌治療剤
|
WO2009033071A2
(en)
|
2007-09-07 |
2009-03-12 |
Dyadic International, Inc. |
Novel fungal enzymes
|
EP2197911A2
(de)
|
2007-09-14 |
2010-06-23 |
Amgen Inc. |
Homogene antikörperpopulationen
|
EP2567969A1
(de)
|
2007-09-24 |
2013-03-13 |
Cornell University |
Immunogene Proteine aus der genombasierten äußeren Membran von Leptospira sowie darauf basierende Zusammensetzungen und Verfahren
|
WO2009041501A1
(ja)
|
2007-09-27 |
2009-04-02 |
Virus Ikagaku Kenkyusho Inc. |
ヘルペスウイルスの潜伏感染に関与する因子及びその利用
|
GB0719231D0
(en)
|
2007-10-03 |
2007-11-14 |
Oxford Genome Sciences Uk Ltd |
Protein
|
US8361465B2
(en)
|
2007-10-26 |
2013-01-29 |
Lpath, Inc. |
Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
|
NZ585556A
(en)
|
2007-11-07 |
2012-07-27 |
Celldex Therapeutics Inc |
Antibodies that bind human dendritic and epithelial cell 205 (dec-205)
|
US8415361B2
(en)
|
2007-11-09 |
2013-04-09 |
The Salk Institute For Biological Studies |
Use of TAM receptor inhibitors as antimicrobials
|
US20090203043A1
(en)
|
2007-11-21 |
2009-08-13 |
Peter Hornbeck |
Protein phosphorylation by basophilic serine/threonine kinases in insulin signaling pathways
|
EP2808345A3
(de)
|
2007-12-05 |
2015-03-11 |
Massachusetts Institute of Technology |
Aglycosylierte Immunoglobulinmutanten
|
MX2010006823A
(es)
|
2007-12-20 |
2010-09-30 |
Xoma Technology Ltd |
Metodos para el tratamiento de la gota.
|
AU2008345022B2
(en)
|
2007-12-28 |
2014-11-06 |
Prothena Biosciences Limited |
Treatment and prophylaxis of amyloidosis
|
SI2242769T1
(sl)
|
2008-01-11 |
2017-02-28 |
Adheron Therapeutics, Inc. |
Protitelesa anti-kadherin-11 EC domene za zdravljenje vnetnih obolenj sklepov
|
ES2796085T3
(es)
|
2008-01-15 |
2020-11-25 |
Univ Leland Stanford Junior |
Marcadores de células madre de leucemia mieloide aguda
|
WO2009092806A2
(en)
|
2008-01-25 |
2009-07-30 |
Aarhus Universitet |
Selective exosite inhibition of papp-a activity against igfbp-4
|
JP2011514167A
(ja)
|
2008-03-17 |
2011-05-06 |
インターセル アーゲー |
肺炎連鎖球菌(S.pneumoniae)に対して保護的なペプチドならびにそれに関連する組成物、方法、および使用
|
WO2009117531A1
(en)
|
2008-03-18 |
2009-09-24 |
Seattle Genetics, Inc. |
Auristatin drug linker conjugates
|
WO2009126306A2
(en)
|
2008-04-10 |
2009-10-15 |
Cell Signaling Technology, Inc. |
Compositions and methods for detecting egfr mutations in cancer
|
EP3062106B1
(de)
|
2008-04-16 |
2020-11-11 |
The Johns Hopkins University |
Verfahren zur bestimmung von varianten des andorgen rezeptors in prostatakrebs
|
WO2009129502A2
(en)
|
2008-04-18 |
2009-10-22 |
The General Hospital Corporation |
Immunotherapies employing self-assembling vaccines
|
GB0807413D0
(en)
|
2008-04-23 |
2008-05-28 |
Ucb Pharma Sa |
Biological products
|
AU2009242453B2
(en)
|
2008-05-02 |
2014-12-04 |
Seagen Inc. |
Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
|
EP2650014A2
(de)
|
2008-06-20 |
2013-10-16 |
Wyeth LLC |
Zusammensetzungen und Verfahren zur Verwendung von ORF1358 von Beta-hämolytischen Streptokokken-stämmen
|
EP2307042B1
(de)
|
2008-06-25 |
2014-03-26 |
H. Lundbeck A/S |
Modulierung des trpv : vps10p domänen-rezeptorsystems zur behandlung von schmerzen
|
JP6100463B2
(ja)
|
2008-06-25 |
2017-03-22 |
エスバテック − ア ノバルティス カンパニー エルエルシー |
TNFαを阻害する安定かつ可溶性の抗体
|
CN102164958A
(zh)
|
2008-06-25 |
2011-08-24 |
艾斯巴技术,爱尔康生物医药研究装置有限责任公司 |
使用通用抗体构架进行的兔抗体的人源化
|
EP2982695B1
(de)
|
2008-07-09 |
2019-04-03 |
Biogen MA Inc. |
Zusammensetzungen mit antikörpern gegen lingo oder fragmenten davon
|
US8148088B2
(en)
|
2008-07-18 |
2012-04-03 |
Abgent |
Regulation of autophagy pathway phosphorylation and uses thereof
|
JP2012504939A
(ja)
|
2008-09-23 |
2012-03-01 |
ワイス・エルエルシー |
架橋結合タンパク質による活性化シグナルの産生を予測するための方法
|
CA2998281C
(en)
|
2008-09-26 |
2022-08-16 |
Dana-Farber Cancer Institute, Inc. |
Human anti-pd-1 antobodies and uses therefor
|
EP2346525A4
(de)
|
2008-10-02 |
2012-05-09 |
Celtaxsys Inc |
Verfahren zur modulation der negativen chemotaxis von immunzellen
|
SI3335728T1
(sl)
|
2008-10-10 |
2020-04-30 |
Children's Medical Center Corporation |
Biokemično stabilizirano HIV-1 ENV trimer cepivo
|
US8871202B2
(en)
|
2008-10-24 |
2014-10-28 |
Lpath, Inc. |
Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
|
EP4104821A1
(de)
|
2008-10-29 |
2022-12-21 |
Ablynx N.V. |
Formulierungen von einzeldomänen-antigen-bindenden molekülen
|
EP2346904B1
(de)
|
2008-10-29 |
2017-04-12 |
China Synthetic Rubber Corporation |
Methoden und mittel zur diagnose und behandlung von hepatozellulärem karzinom
|
JP6113404B2
(ja)
|
2008-10-29 |
2017-04-12 |
アブリンクス エン.ヴェー. |
単一ドメイン抗原結合分子の精製方法
|
DK2356135T3
(en)
|
2008-11-05 |
2017-12-04 |
Wyeth Llc |
IMMUNOGEN MULTICOMPONENT COMPOSITION FOR THE PREVENTION OF BETA-HAEMOLYTIC STRUCTURAL TOC (BHS) DISEASE
|
CN102292101A
(zh)
|
2008-11-26 |
2011-12-21 |
五佳医疗股份有限公司 |
通过serpine2来调节胶原和平滑肌肌动蛋白表达的组合物和方法
|
AU2009323996A1
(en)
|
2008-12-03 |
2011-07-07 |
Institut Pasteur |
Use of phenol-soluble modulins for vaccine development
|
US8401799B2
(en)
|
2008-12-05 |
2013-03-19 |
Lpath, Inc. |
Antibody design using anti-lipid antibody crystal structures
|
EP3165537A1
(de)
|
2008-12-19 |
2017-05-10 |
H. Lundbeck A/S |
Modulation der vps-10-domänen-rezeptor-familie für die behandlung von psychischen und verhaltensstörungen
|
US20120003235A1
(en)
|
2008-12-31 |
2012-01-05 |
Biogen Idec Ma Inc. |
Anti-lymphotoxin antibodies
|
US9181315B2
(en)
|
2009-01-08 |
2015-11-10 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for induced brown fat differentiation
|
WO2010084408A2
(en)
|
2009-01-21 |
2010-07-29 |
Oxford Biotherapeutics Ltd. |
Pta089 protein
|
US8313915B2
(en)
|
2009-01-21 |
2012-11-20 |
Gundersen Lutheran Medical Foundation, Inc. |
Early detection of canine lyme disease by specific peptides and antibodies
|
US8530629B2
(en)
|
2009-01-30 |
2013-09-10 |
Ab Biosciences, Inc. |
Lowered affinity antibodies and uses therefor
|
CA2983133A1
(en)
|
2009-02-04 |
2010-08-12 |
Molecular Innovations |
Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin, and antibodies used therein
|
CN102741287B
(zh)
|
2009-02-17 |
2015-02-18 |
Ucb制药公司 |
对人ox40具有特异性的抗体分子
|
US20110306069A1
(en)
|
2009-02-19 |
2011-12-15 |
Qingyu Wu |
Corin As A Marker For Heart Failure
|
ES2589769T3
(es)
|
2009-02-27 |
2016-11-16 |
Massachusetts Institute Of Technology |
Proteínas modificadas con alta afinidad por quelatos de DOTA
|
GB0904214D0
(en)
|
2009-03-11 |
2009-04-22 |
Ucb Pharma Sa |
Biological products
|
JP2010213694A
(ja)
|
2009-03-12 |
2010-09-30 |
Wyeth Llc |
PKN3/RhoC高分子複合体およびその使用方法
|
JP2012522749A
(ja)
|
2009-04-01 |
2012-09-27 |
グラクソ グループ リミテッド |
抗il−23免疫グロブリン
|
WO2010112034A2
(en)
|
2009-04-02 |
2010-10-07 |
Aarhus Universitet |
Compositions and methods for treatment and diagnosis of synucleinopathies
|
EP3061460A1
(de)
|
2009-04-10 |
2016-08-31 |
Tufts Medical Center, Inc. |
Par-1-aktivierung mittels metalloproteinase-1 (mmp-1)
|
US20120135005A1
(en)
|
2009-04-16 |
2012-05-31 |
Harding Fiona A |
ANTI-TNF-a ANTIBODIES AND THEIR USES
|
WO2010121093A2
(en)
|
2009-04-17 |
2010-10-21 |
Lpath, Inc. |
Humanized antibody compositions and methods for binding lysophosphatidic acid
|
EP3524275A1
(de)
|
2009-04-22 |
2019-08-14 |
Massachusetts Institute Of Technology |
Angeborene immununterdrückung ermöglicht die wiederholte verabreichung von langen rna-molekülen
|
JP5781501B2
(ja)
|
2009-04-22 |
2015-09-24 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung |
改変されたFcRn結合部位を有する抗体融合タンパク質
|
ES2598006T3
(es)
|
2009-04-24 |
2017-01-24 |
Vanderbilt University |
Anticuerpos anti-TGF-beta para la inducción del crecimiento óseo
|
ES2725356T3
(es)
|
2009-04-29 |
2019-09-23 |
Henry M Jackson Found Advancement Military Medicine Inc |
Anticuerpos monoclonales de ERG2 y su uso terapéutico
|
CN102459628A
(zh)
|
2009-05-13 |
2012-05-16 |
基酶有限公司 |
抗人cd52 免疫球蛋白
|
PE20120622A1
(es)
|
2009-06-17 |
2012-05-26 |
Abbott Biotherapeutics Corp |
Anticuerpos anti-vegf y sus usos
|
EP2445531A4
(de)
|
2009-06-24 |
2013-04-24 |
Lpath Inc |
Verfahren für erhöhte neuronale differenzierung mithilfe von antikörpern gegen lysophosphatidsäure
|
US8399625B1
(en)
|
2009-06-25 |
2013-03-19 |
ESBATech, an Alcon Biomedical Research Unit, LLC |
Acceptor framework for CDR grafting
|
EP2272979A1
(de)
|
2009-06-30 |
2011-01-12 |
Centre National de la Recherche Scientifique (CNRS) |
Verfahren zum Testen einer Person, die eine Prädisposition für Krebs aufzuweisen scheint
|
US20120226119A1
(en)
|
2009-07-09 |
2012-09-06 |
Hoffmann-La Roche Inc. |
Vivo tumor vasculature imaging
|
EP2475682B1
(de)
|
2009-09-10 |
2018-01-31 |
UCB Biopharma SPRL |
Polyvalente antikörper
|
EP2477647B1
(de)
|
2009-09-14 |
2016-01-13 |
The Regents of the University of Colorado |
Modulation von immuntherapeutischen produkten auf hefebasis und reaktionen
|
EP2470564A1
(de)
|
2009-10-22 |
2012-07-04 |
Yeda Research and Development Co. Ltd. |
Zusammensetzungen und verfahren zur behandlung von aspergillose
|
EP2493929B1
(de)
|
2009-10-28 |
2017-08-16 |
AbbVie Biotherapeutics Inc. |
Anti-egfr-antikörper und deren verwendungen
|
US20120282177A1
(en)
|
2009-11-02 |
2012-11-08 |
Christian Rohlff |
ROR1 as Therapeutic and Diagnostic Target
|
WO2011054359A2
(en)
|
2009-11-06 |
2011-05-12 |
University Of Copenhagen |
Method for early detection of cancer
|
CA3061784C
(en)
|
2009-11-13 |
2023-09-26 |
Dana-Farber Cancer Institute, Inc. |
Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
|
GB0920127D0
(en)
|
2009-11-17 |
2009-12-30 |
Ucb Pharma Sa |
Antibodies
|
GB0920324D0
(en)
|
2009-11-19 |
2010-01-06 |
Ucb Pharma Sa |
Antibodies
|
US9872905B2
(en)
|
2009-12-01 |
2018-01-23 |
President And Fellows Of Harvard College |
Modulation of NK cell antigen specific effector activity by modulation of CXCR6 (CD186)
|
WO2011071883A1
(en)
|
2009-12-07 |
2011-06-16 |
Decimmune Therapeutics, Inc. |
Anti-inflammatory antibodies and uses therefor
|
WO2011075578A1
(en)
|
2009-12-16 |
2011-06-23 |
Philip Bosch |
Methods of treating interstitial cystitis
|
ES2594893T3
(es)
|
2009-12-16 |
2016-12-23 |
Abbvie Biotherapeutics Inc. |
Anticuerpos anti HER2 y sus usos
|
GB201000467D0
(en)
|
2010-01-12 |
2010-02-24 |
Ucb Pharma Sa |
Antibodies
|
GB201000588D0
(en)
|
2010-01-14 |
2010-03-03 |
Ucb Pharma Sa |
Bacterial host strain
|
JP2013520162A
(ja)
|
2010-01-22 |
2013-06-06 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
代謝障害の同定、査定、予防および治療のための組成物、キットおよび方法
|
CN102971342B
(zh)
|
2010-01-28 |
2016-08-03 |
Ab生物科学公司 |
亲和力降低的新抗体和制备所述抗体的方法
|
CA2789168A1
(en)
|
2010-02-02 |
2011-08-11 |
Abbott Biotechnology Ltd. |
Methods and compositions for predicting responsiveness to treatment with tnf-.alpha. inhibitor
|
TWI518325B
(zh)
|
2010-02-04 |
2016-01-21 |
自治醫科大學 |
對alk抑制劑具有先抗性或後抗性癌症的識別、判斷和治療
|
WO2011106885A1
(en)
|
2010-03-03 |
2011-09-09 |
The University Of British Columbia |
Oligomer-specific amyloid beta epitope and antibodies
|
TW201134488A
(en)
|
2010-03-11 |
2011-10-16 |
Ucb Pharma Sa |
PD-1 antibodies
|
US8993731B2
(en)
|
2010-03-11 |
2015-03-31 |
Ucb Biopharma Sprl |
PD-1 antibody
|
WO2011119484A1
(en)
|
2010-03-23 |
2011-09-29 |
Iogenetics, Llc |
Bioinformatic processes for determination of peptide binding
|
GB201005064D0
(en)
|
2010-03-25 |
2010-05-12 |
Ucb Pharma Sa |
Biological products
|
US10472426B2
(en)
|
2010-03-25 |
2019-11-12 |
Ucb Biopharma Sprl |
Disulfide stabilized DVD-Ig molecules
|
US10745467B2
(en)
|
2010-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
US20150231215A1
(en)
|
2012-06-22 |
2015-08-20 |
Randolph J. Noelle |
VISTA Antagonist and Methods of Use
|
NZ602634A
(en)
|
2010-03-26 |
2015-06-26 |
Dartmouth College |
Vista regulatory t cell mediator protein, vista binding agents and use thereof
|
EP2556374A1
(de)
|
2010-04-05 |
2013-02-13 |
Wyeth LLC |
Biomarker für p13k-ausgelösten krebs
|
SI3202789T1
(sl)
|
2010-04-16 |
2020-11-30 |
Biogen Ma Inc. |
Protitelesa anti-vla 4
|
CA2796186C
(en)
|
2010-04-21 |
2019-04-09 |
Abbott Biotechnology Ltd. |
Wearable automatic injection device for controlled delivery of therapeutic agents
|
WO2011133658A1
(en)
|
2010-04-22 |
2011-10-27 |
Boston Medical Center Corporation |
Compositions and methods for targeting and delivering therapeutics into cells
|
EP2380909A1
(de)
|
2010-04-26 |
2011-10-26 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
An Brustkrebs beteiligtes Protein PTK-7
|
US9146241B2
(en)
|
2011-11-23 |
2015-09-29 |
Board Of Regents, The University Of Texas System |
Proteomic identification of antibodies
|
WO2011146727A1
(en)
|
2010-05-19 |
2011-11-24 |
Philip Bosch |
Methods of treating interstitial cystitis
|
US8747854B2
(en)
|
2010-06-03 |
2014-06-10 |
Abbvie Biotechnology Ltd. |
Methods of treating moderate to severe hidradenitis suppurativa with anti-TNF-alpha antibodies
|
CA2803391C
(en)
|
2010-06-22 |
2021-11-09 |
Neogenix Oncology, Inc. |
Npc1 antibodies that bind a muc5ac epitope
|
SI2593128T1
(en)
|
2010-07-15 |
2018-08-31 |
Adheron Therapeutics, Inc. |
Humanized antibodies targeting the EC1 Kaderina-11 domain and associated compositions and procedures
|
WO2012009705A1
(en)
|
2010-07-15 |
2012-01-19 |
Zyngenia, Inc. |
Ang-2 binding complexes and uses thereof
|
JP2013536175A
(ja)
|
2010-07-16 |
2013-09-19 |
アブリンクス エン.ヴェー. |
修飾された単一ドメイン抗原結合分子及びその使用
|
GB201012599D0
(en)
|
2010-07-27 |
2010-09-08 |
Ucb Pharma Sa |
Process for purifying proteins
|
EP2420250A1
(de)
|
2010-08-13 |
2012-02-22 |
Universitätsklinikum Münster |
Anti-Syndecan-4-Antikörper
|
CA2807607A1
(en)
|
2010-08-20 |
2012-02-23 |
Wyeth Llc |
Cell culture of growth factor-free adapted cells
|
GB201014033D0
(en)
|
2010-08-20 |
2010-10-06 |
Ucb Pharma Sa |
Biological products
|
ME02678B
(de)
|
2010-08-23 |
2017-06-20 |
Univ Texas |
Anti-ox40-antikörper und verfahren zu deren verwendung
|
MX350142B
(es)
|
2010-08-23 |
2017-08-28 |
Wyeth Llc * |
Formulaciones estables de antigenos rlp2086 de neisseria meningitidis.
|
EP3549601B1
(de)
|
2010-09-10 |
2021-02-24 |
Wyeth LLC |
Non-lipidierten varianten von neisseria meningitidis orf2086 antigene
|
CA3182320A1
(en)
|
2010-09-23 |
2012-03-29 |
Precision Biologics, Inc. |
Colon and pancreas cancer peptidomimetics
|
UA112062C2
(uk)
|
2010-10-04 |
2016-07-25 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
Cd33-зв'язувальний агент
|
AR083495A1
(es)
|
2010-10-22 |
2013-02-27 |
Esbatech Alcon Biomed Res Unit |
Anticuerpos estables y solubles
|
AU2011319777B2
(en)
|
2010-10-27 |
2016-12-08 |
The Research Foundation For The State University Of New York |
Compositions targeting the soluble extracellular domain of E-cadherin and related methods for cancer therapy
|
US9539427B2
(en)
|
2010-11-08 |
2017-01-10 |
The Johns Hopkins University |
Methods for improving heart function
|
WO2012068463A2
(en)
|
2010-11-18 |
2012-05-24 |
Beth Israel Deaconess Medicall Center, Inc. |
Methods of treating obesity by inhibiting nicotinamide n-methyl transferase (nnmt)
|
MX361929B
(es)
|
2010-11-19 |
2018-12-19 |
Eisai R&D Man Co Ltd Star |
Anticuerpos anti-ligando de quimiocina cc 20 (ccl20) neutralizantes.
|
ES2847891T3
(es)
|
2010-11-23 |
2021-08-04 |
Vitaeris Inc |
Anticuerpos anti-IL-6 para el tratamiento de la mucositis oral
|
KR101947356B1
(ko)
|
2010-11-23 |
2019-02-12 |
글락소 그룹 리미티드 |
온코스타틴 m (osm)에 대한 항원 결합 단백질
|
CN103415615B
(zh)
|
2010-11-24 |
2015-11-25 |
高红 |
扩增造血干细胞
|
KR20200023495A
(ko)
|
2011-01-10 |
2020-03-04 |
더 리젠츠 오브 더 유니버시티 오브 미시간 |
줄기 세포 인자 억제제
|
ME02734B
(de)
|
2011-01-14 |
2017-10-20 |
Ucb Biopharma Sprl |
Antikörpermodule zur bindung an il-17a und il-17f
|
AU2012209223B2
(en)
|
2011-01-24 |
2015-11-05 |
Abbvie Biotechnology Ltd |
Automatic injection devices having overmolded gripping surfaces
|
MY164530A
(en)
|
2011-03-02 |
2017-12-29 |
Berg Llc |
Interrogatory cell-based assays and uses thereof
|
MX361242B
(es)
|
2011-03-30 |
2018-11-30 |
Ablynx Nv |
Anticuerpos de dominio sencillo contra tnf-alfa y usos de los mismos.
|
US20120328567A1
(en)
|
2011-04-08 |
2012-12-27 |
Steven Bushnell |
Biomarkers predictive of therapeutic responsiveness to ifnb and uses thereof
|
CN103702682A
(zh)
|
2011-04-21 |
2014-04-02 |
科罗拉多州立大学董事会法人团体 |
治疗视神经脊髓炎的组合物和方法
|
MX345747B
(es)
|
2011-04-21 |
2017-02-14 |
Abbvie Inc |
Dispositivo de inyección automático portable.
|
UA116189C2
(uk)
|
2011-05-02 |
2018-02-26 |
Мілленніум Фармасьютікалз, Інк. |
КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
|
KR102493433B1
(ko)
|
2011-05-02 |
2023-01-27 |
밀레니엄 파머슈티컬스 인코퍼레이티드 |
항-α4β7 항체에 대한 제형
|
US20140086827A1
(en)
|
2011-05-09 |
2014-03-27 |
The Cleveland Clinic Foundation |
Serum S100B And Uses Thereof
|
ES2704038T3
(es)
|
2011-05-24 |
2019-03-13 |
Zyngenia Inc |
Complejos multiespecíficos multivalentes y monovalentes y sus usos
|
JP6342325B2
(ja)
|
2011-05-25 |
2018-06-13 |
イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. |
炎症性障害の治療のための抗kir抗体
|
LT3415531T
(lt)
|
2011-05-27 |
2023-09-25 |
Glaxo Group Limited |
Bcma (cd269/tnfrsf17) – surišantys baltymai
|
EP2537933A1
(de)
|
2011-06-24 |
2012-12-26 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Auf IL-15- und IL-15Ralpha-Sushi-Domäne basierende Immunozytokine
|
LT2726094T
(lt)
|
2011-06-28 |
2017-02-10 |
Oxford Biotherapeutics Ltd |
Gydymo ir diagnozavimo objektas
|
AU2012275133B2
(en)
|
2011-06-30 |
2017-08-17 |
Genzyme Corporation |
Inhibitors of T-cell activation
|
EP3339325A1
(de)
|
2011-07-13 |
2018-06-27 |
UCB Biopharma SPRL |
Bakterienwirtsstamm zur expression von rekombinanter dsbc
|
EP2546267A1
(de)
|
2011-07-13 |
2013-01-16 |
UCB Pharma S.A. |
Bakterienwirtsstamm mit rekombinanter DsbC-Expression
|
US20150125533A1
(en)
|
2011-07-25 |
2015-05-07 |
American University In Cairo |
Single-domain antibodies and graphene coated magnetic metal nanoparticles conjugate and methods for using the same
|
WO2013028810A1
(en)
|
2011-08-22 |
2013-02-28 |
Cangene Corporation |
Clostridium difficile antibodies
|
EP3564261A1
(de)
|
2011-08-23 |
2019-11-06 |
Foundation Medicine, Inc. |
Kif5b-re-fusionsmoleküle und verwendungen davon
|
WO2013036596A2
(en)
|
2011-09-06 |
2013-03-14 |
Reed Guy L |
Serpinf2-binding molecules and methods of use
|
UY34317A
(es)
|
2011-09-12 |
2013-02-28 |
Genzyme Corp |
Anticuerpo antireceptor de célula T (alfa)/ß
|
US8969519B2
(en)
|
2011-09-13 |
2015-03-03 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for brown fat induction and activity using FNDC5
|
EP2771349B1
(de)
|
2011-09-16 |
2020-02-26 |
Iogenetics, LLC. |
Bioinformatikverfahren zur bestimmung von peptidbindungen
|
WO2013038156A1
(en)
|
2011-09-16 |
2013-03-21 |
Ucb Pharma S.A. |
Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile
|
AU2012311492A1
(en)
|
2011-09-23 |
2014-03-06 |
Amgen Research (Munich) Gmbh |
Bispecific binding molecules for 5T4 and CD3
|
WO2013054320A1
(en)
|
2011-10-11 |
2013-04-18 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
|
US10378060B2
(en)
|
2011-10-14 |
2019-08-13 |
Dana-Farber Cancer Institute, Inc. |
ZNF365/ZFP365 biomarker predictive of anti-cancer response
|
AU2012324495B2
(en)
|
2011-10-21 |
2016-04-21 |
Pfizer Inc. |
Addition of iron to improve cell culture
|
UA112203C2
(uk)
|
2011-11-11 |
2016-08-10 |
Юсб Фарма С.А. |
Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對bcma之e3以及cd3的結合分子
|
PL2780039T3
(pl)
|
2011-11-17 |
2018-03-30 |
Pfizer Inc. |
Cytotoksyczne peptydy i ich koniugaty przeciwciało lek
|
EP2599496A1
(de)
|
2011-11-30 |
2013-06-05 |
Kenta Biotech AG |
Neuartige Targets von Acinetobacter baumannii
|
US20150017157A1
(en)
|
2011-12-19 |
2015-01-15 |
Xoma (Us) Llc |
Methods for treating acne
|
GB201203071D0
(en)
|
2012-02-22 |
2012-04-04 |
Ucb Pharma Sa |
Biological products
|
GB201203051D0
(en)
|
2012-02-22 |
2012-04-04 |
Ucb Pharma Sa |
Biological products
|
EP2820047B1
(de)
|
2012-03-01 |
2018-04-25 |
Amgen Research (Munich) GmbH |
Langlebige polypeptidbindungsmoleküle
|
SA115360586B1
(ar)
|
2012-03-09 |
2017-04-12 |
فايزر انك |
تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
|
MX359256B
(es)
|
2012-03-09 |
2018-09-19 |
Pfizer |
Composiciones de neisseria meningitidis y metodos de las mismas.
|
US20140080180A1
(en)
|
2012-03-27 |
2014-03-20 |
Genentech, Inc. |
Harvest operations for recombinant proteins
|
WO2013150518A1
(en)
|
2012-04-01 |
2013-10-10 |
Rappaport Family Institute For Research In The Medical Sciences |
Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies
|
KR20200105524A
(ko)
|
2012-04-02 |
2020-09-07 |
버그 엘엘씨 |
조사적 세포 기반 분석 및 이의 사용
|
WO2013152011A1
(en)
|
2012-04-02 |
2013-10-10 |
Ab Biosciences, Inc. |
Novel human control antibodies and uses therefor
|
EP2834641A1
(de)
|
2012-04-02 |
2015-02-11 |
Gundersen Lutheran Health Systems, Inc. |
Reagenzien, verfahren und kits zur klassifizierung von krebs
|
GB201208370D0
(en)
|
2012-05-14 |
2012-06-27 |
Ucb Pharma Sa |
Antibodies
|
AU2013262934B2
(en)
|
2012-05-14 |
2018-02-01 |
Biogen Ma Inc. |
LINGO-2 antagonists for treatment of conditions involving motor neurons
|
NZ724892A
(en)
|
2012-05-15 |
2018-04-27 |
Seattle Genetics Inc |
Self-stabilizing linker conjugates
|
US9890215B2
(en)
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
CN104619722B
(zh)
|
2012-06-22 |
2022-10-04 |
达特茅斯大学理事会 |
新型vista-ig构建体和vista-ig用于治疗自身免疫性、过敏性和炎性疾病的用途
|
GB201213652D0
(en)
|
2012-08-01 |
2012-09-12 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
EP3613765A1
(de)
|
2012-08-03 |
2020-02-26 |
Dana-Farber Cancer Institute, Inc. |
Antikörper gegen abstossungs führung molekül b (rgmb)
|
CA2882034C
(en)
|
2012-08-16 |
2019-10-29 |
Ipierian, Inc. |
Methods of treating a tauopathy
|
WO2014029752A1
(en)
|
2012-08-22 |
2014-02-27 |
Glaxo Group Limited |
Anti lrp6 antibodies
|
EP2892558B1
(de)
|
2012-09-07 |
2019-04-10 |
The Trustees Of Dartmouth College |
Vista-modulatoren zur diagnose und behandlung von krebs
|
EP3677310A1
(de)
|
2012-10-08 |
2020-07-08 |
St. Jude Children's Research Hospital |
Therapien auf der basis der steuerung der stabilität und funktion regulatorischer t-zellen über eine neuropilin-1:semaphorin-achse
|
KR20210063443A
(ko)
|
2012-10-09 |
2021-06-01 |
바이오젠 엠에이 인코포레이티드 |
탈수초성 질환의 치료를 위한 복합 요법 및 용도
|
CN110818798A
(zh)
|
2012-10-25 |
2020-02-21 |
美国比奥维拉迪维股份有限公司 |
抗补体C1s抗体和其用途
|
WO2014066733A2
(en)
|
2012-10-25 |
2014-05-01 |
Life Technologies Corporation |
Methods and compositions for enzyme-mediated site-specific radiolabeling of glycoproteins
|
AU2013337638B2
(en)
|
2012-11-02 |
2018-10-25 |
Bioverativ Usa Inc. |
Anti-complement C1s antibodies and uses thereof
|
WO2014071358A2
(en)
|
2012-11-05 |
2014-05-08 |
Foundation Medicine, Inc. |
Novel ntrk1 fusion molecules and uses thereof
|
AU2013340449B2
(en)
|
2012-11-05 |
2017-11-30 |
Pfizer Inc. |
Spliceostatin analogs
|
TWI589590B
(zh)
|
2012-11-07 |
2017-07-01 |
輝瑞股份有限公司 |
抗切口3(anti-notch3)抗體及抗體-藥物共軛體
|
US20140154255A1
(en)
|
2012-11-30 |
2014-06-05 |
Abbvie Biotherapeutics Inc. |
Anti-vegf antibodies and their uses
|
US9353150B2
(en)
|
2012-12-04 |
2016-05-31 |
Massachusetts Institute Of Technology |
Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
|
US10024844B2
(en)
|
2012-12-20 |
2018-07-17 |
Hospital For Special Surgery |
Identification of an inhibitor of iRhom1 or an inhibitor of iRhom2
|
GB201223276D0
(en)
|
2012-12-21 |
2013-02-06 |
Ucb Pharma Sa |
Antibodies and methods of producing same
|
US9938344B2
(en)
|
2012-12-28 |
2018-04-10 |
Precision Biologics, Inc. |
Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
|
WO2014113729A2
(en)
|
2013-01-18 |
2014-07-24 |
Foundation Mecicine, Inc. |
Methods of treating cholangiocarcinoma
|
GB201302447D0
(en)
|
2013-02-12 |
2013-03-27 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
WO2014134179A1
(en)
|
2013-02-28 |
2014-09-04 |
The Board Of Regents Of The University Of Texas System |
Methods for classifying a cancer as susceptible to tmepai-directed therapies and treating such cancers
|
EP2964665B1
(de)
|
2013-03-08 |
2018-08-01 |
Pfizer Inc |
Immunogene fusionspolypeptide
|
US10023608B1
(en)
|
2013-03-13 |
2018-07-17 |
Amgen Inc. |
Protein purification methods to remove impurities
|
US9023353B2
(en)
|
2013-03-13 |
2015-05-05 |
The Board Of Trustees Of The University Of Arkansas |
Anti-(+)—methamphetamine monoclonal antibodies
|
CA2904170A1
(en)
|
2013-03-14 |
2014-09-25 |
University Of Maryland, Baltimore |
Androgen receptor down-regulating agents and uses thereof
|
AU2014236309A1
(en)
|
2013-03-14 |
2015-10-29 |
Ren Liu |
Cancer treatment using antibodies that bing cell surface GRP78
|
AR095199A1
(es)
|
2013-03-15 |
2015-09-30 |
Genzyme Corp |
Anticuerpos anti-cd52
|
EP2970489A2
(de)
|
2013-03-15 |
2016-01-20 |
AbbVie Biotechnology Ltd |
Anti-cd25-antikörper und deren verwendungen
|
MX368665B
(es)
|
2013-03-15 |
2019-10-10 |
Abbvie Biotherapeutics Inc |
Variantes de fc.
|
CN105358174B
(zh)
|
2013-03-15 |
2019-03-15 |
酵活有限公司 |
具细胞毒性和抗有丝分裂的化合物以及其使用方法
|
BR112015023752B1
(pt)
|
2013-03-15 |
2023-11-14 |
Zyngenia, Inc. |
Domínio de reconhecimento modular (mrd), complexo compreendendo mrd e cetuximabe, usos do complexo para inibir a angiogênese e tratar câncer e composição farmacêutica compreendendo o dito complexo
|
AU2014233478A1
(en)
|
2013-03-15 |
2015-09-24 |
Abbvie Biotechnology Ltd. |
Anti-CD25 antibodies and their uses
|
AR095374A1
(es)
|
2013-03-15 |
2015-10-14 |
Amgen Res (Munich) Gmbh |
Moléculas de unión para bcma y cd3
|
HUE058364T2
(hu)
|
2013-04-19 |
2022-07-28 |
Cytune Pharma |
Citokinbõl származó kezelés redukált vaszkuláris permeabilitási szindrómával
|
US20160089434A1
(en)
|
2013-06-03 |
2016-03-31 |
Novartis Ag |
Combinations of an anti-pd-l1 antibody and a mek inhibitor and/or a braf inhibitor
|
EP3293275B1
(de)
|
2013-06-06 |
2021-08-04 |
Dana-Farber Cancer Institute, Inc. |
Zusammensetzung und verfahren zur identifikation, beurteilung, vorbeugung und behandlung von krebs mit pd-l1-isoformen
|
CA2914768A1
(en)
|
2013-06-10 |
2014-12-18 |
Ipierian, Inc. |
Methods of treating a tauopathy
|
US9587032B2
(en)
|
2013-06-12 |
2017-03-07 |
The Board Of Trustees Of The Leland Stanford Junior University |
IgE antibodies for the inhibition of tumor metastasis
|
US9428748B2
(en)
|
2013-06-17 |
2016-08-30 |
Hong Gao |
Method of expanding hematopoietic stem cells
|
EP3011334A1
(de)
|
2013-06-20 |
2016-04-27 |
The Trustees Of The University Of Pennsylvania |
Verfahren zur diagnose von bauchspeicheldrüsenkrebs
|
WO2015006554A1
(en)
|
2013-07-10 |
2015-01-15 |
The Regents Of The University Of Michigan |
Therapeutic antibodies and uses thereof
|
US10208125B2
(en)
|
2013-07-15 |
2019-02-19 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Anti-mucin 1 binding agents and uses thereof
|
AU2014296288B2
(en)
|
2013-07-31 |
2020-02-13 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for modulating thermogenesis using PTH-related and EGF-related molecules
|
CN105636594A
(zh)
|
2013-08-12 |
2016-06-01 |
托凯药业股份有限公司 |
使用雄激素靶向疗法用于治疗肿瘤性疾病的生物标记物
|
GB201315487D0
(en)
|
2013-08-30 |
2013-10-16 |
Ucb Pharma Sa |
Antibodies
|
WO2015035044A2
(en)
|
2013-09-04 |
2015-03-12 |
Abbvie Biotherapeutics Inc. |
Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
|
RU2662968C2
(ru)
|
2013-09-08 |
2018-07-31 |
Пфайзер Инк. |
Иммуногенная композиция против neisseria meningitidis (варианты)
|
AU2014326974B2
(en)
|
2013-09-24 |
2017-01-19 |
The Feinstein Institute For Medical Research |
Peptides inhibiting cold-inducible RNA binding protein activity
|
PT3049085T
(pt)
|
2013-09-26 |
2021-10-01 |
Beth Israel Deaconess Medical Ct Inc |
Inibidores de sgk1 no tratamento da síndrome do qt longo
|
EP3757130A1
(de)
|
2013-09-26 |
2020-12-30 |
Costim Pharmaceuticals Inc. |
Verfahren zur behandlung von blutkrebs
|
NZ717668A
(en)
|
2013-10-15 |
2024-03-22 |
Seagen Inc |
Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
|
GB201320066D0
(en)
|
2013-11-13 |
2013-12-25 |
Ucb Pharma Sa |
Biological products
|
KR102283408B1
(ko)
|
2013-11-15 |
2021-07-29 |
앵스티띠 파스퇴르 |
플라스모듐 팔시파룸 아르테미시닌 내성의 분자 마커
|
WO2015081085A2
(en)
|
2013-11-27 |
2015-06-04 |
Ipierian, Inc. |
Methods of treating a tauopathy
|
EP3080161B1
(de)
|
2013-12-09 |
2021-03-24 |
New York University |
Zusammensetzungen und verfahren zur phagozytenfreisetzung von antistaphylokokkenmittel
|
WO2015091653A2
(en)
|
2013-12-17 |
2015-06-25 |
Westfaelische Wilhelms-Universitaet Muenster |
Means and methods for treating a pruritus-like skin-disease
|
EP3082878B1
(de)
|
2013-12-19 |
2022-10-05 |
Seagen Inc. |
Methylencarbamat-linker zur verwendung mit gezielten wirkstoffkonjugaten
|
WO2015095868A1
(en)
|
2013-12-20 |
2015-06-25 |
Wake Forest University Health Sciences |
Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
|
EP2960252A1
(de)
|
2014-06-26 |
2015-12-30 |
Institut Pasteur |
Phospholipase zur Behandlung von Immunosuppression
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
JP6590810B2
(ja)
|
2013-12-24 |
2019-10-16 |
ヤンセン ファーマシューティカ エヌブイ |
抗vista抗体および断片
|
PL3086815T3
(pl)
|
2013-12-27 |
2022-06-13 |
Zymeworks Inc. |
Układy łącznikowe dla koniugatów leków zawierające ugrupowanie sulfonamidowe
|
WO2015103026A2
(en)
|
2014-01-03 |
2015-07-09 |
The Regents Of The University Of Michigan |
Treatment of neurological disorders
|
JP6682438B2
(ja)
|
2014-01-09 |
2020-04-15 |
ハダシット メディカル リサーチ サービシーズ アンド ディベロップメント リミテッドHadasit Medical Research Services and Development Ltd. |
癌治療のための改善された細胞組成物および方法
|
EP3094736A4
(de)
|
2014-01-14 |
2017-10-25 |
Dana-Farber Cancer Institute, Inc. |
Zusammensetzungen und verfahren zur identifikation, beurteilung, vorbeugung und behandlung von melanom mit pd-l1-isoformen
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
EP3099692B9
(de)
|
2014-01-27 |
2019-11-13 |
Pfizer Inc |
Bifunktionelle zytostatika
|
WO2015116753A1
(en)
|
2014-01-29 |
2015-08-06 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against the muc1-c/extracellular domain (muc1-c/ecd)
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
CA3212977A1
(en)
|
2014-02-11 |
2015-08-20 |
Visterra, Inc. |
Antibody molecules to dengue virus and uses thereof
|
SG11201605886RA
(en)
|
2014-02-17 |
2016-09-29 |
Seattle Genetics Inc |
Hydrophilic antibody-drug conjugates
|
EP3145546B1
(de)
|
2014-02-19 |
2020-12-09 |
Emergent BioSolutions Canada Inc. |
Monoklonale marburg-antikörper
|
EP2915569A1
(de)
|
2014-03-03 |
2015-09-09 |
Cytune Pharma |
Reinigungsverfahren für Il-15/Il-15Ralpha-basierte Konjugate
|
AU2015229103C9
(en)
|
2014-03-14 |
2020-11-26 |
Immutep S.A.S |
Antibody molecules to LAG-3 and uses thereof
|
US10544395B2
(en)
|
2014-03-19 |
2020-01-28 |
Pfizer Inc. |
Method of cell culture
|
WO2015145449A2
(en)
|
2014-03-27 |
2015-10-01 |
Yeda Research And Development Co. Ltd. |
T-cell receptor cdr3 peptides and antibodies
|
SG11201607258SA
(en)
|
2014-04-10 |
2016-10-28 |
Obi Pharma Inc |
Antibodies, pharmaceutical compositions and uses thereof
|
US11624093B2
(en)
|
2014-04-24 |
2023-04-11 |
Dana-Farber Cancer Institute, Inc. |
Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
|
WO2015164364A2
(en)
|
2014-04-25 |
2015-10-29 |
The Brigham And Women's Hospital, Inc. |
Methods to manipulate alpha-fetoprotein (afp)
|
CR20160534A
(es)
|
2014-04-27 |
2017-04-25 |
Ccam Biotherapeutics Ltd |
Anticuerpos humanizados contra la molécula de adhesión celular relacionada al antígeno carcinoembriónico 1 (ceacam1)
|
US11427647B2
(en)
|
2014-04-27 |
2022-08-30 |
Famewave Ltd. |
Polynucleotides encoding humanized antibodies against CEACAM1
|
IL248511B
(en)
|
2014-05-13 |
2022-07-01 |
Bavarian Nordic As |
Combined therapy for the treatment of cancer with a focovirus expressing the antigen and a monoclonal antibody against tim-3
|
US10774387B2
(en)
|
2014-05-19 |
2020-09-15 |
The Johns Hopkins University |
Methods for identifying androgen receptor splice variants in subjects having castration resistant prostate cancer
|
GB201409558D0
(en)
|
2014-05-29 |
2014-07-16 |
Ucb Biopharma Sprl |
Method
|
MX2016016310A
(es)
|
2014-06-11 |
2017-10-20 |
A Green Kathy |
Uso de agonistas y antagonistas vista para suprimir o aumentar la inmunidad humoral.
|
GB201411320D0
(en)
|
2014-06-25 |
2014-08-06 |
Ucb Biopharma Sprl |
Antibody construct
|
GB201412658D0
(en)
|
2014-07-16 |
2014-08-27 |
Ucb Biopharma Sprl |
Molecules
|
GB201412659D0
(en)
|
2014-07-16 |
2014-08-27 |
Ucb Biopharma Sprl |
Molecules
|
EP3808756A1
(de)
|
2014-07-17 |
2021-04-21 |
The Trustees of The University of Pennsylvania |
Verfahren zur verwendung von exosomen zur überwachung des zustands eines transplantierten organs
|
WO2016012623A1
(en)
|
2014-07-25 |
2016-01-28 |
Theravectys |
Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule
|
UY36245A
(es)
|
2014-07-31 |
2016-01-29 |
Amgen Res Munich Gmbh |
Constructos de anticuerpos para cdh19 y cd3
|
MX2017001403A
(es)
|
2014-07-31 |
2017-07-07 |
Amgen Res (Munich) Gmbh |
Constructo de anticuerpo de cadena individual biespecifico con distribucion mejorada de tejido.
|
TW201609812A
(zh)
|
2014-07-31 |
2016-03-16 |
安美基研究(慕尼黑)公司 |
最佳化之跨物種特異性雙特異性單鏈抗體構築體
|
CN106794246B
(zh)
|
2014-08-08 |
2021-10-15 |
OncoQuest制药有限公司 |
肿瘤抗原特异性抗体和tlr3刺激以增强检查点干扰癌症疗法的性能
|
WO2016025202A1
(en)
|
2014-08-14 |
2016-02-18 |
The Regents Of The University Of Colorado |
Antibody-sirna conjugates and uses therefor
|
EP3186393A4
(de)
|
2014-08-25 |
2018-01-10 |
The Johns Hopkins University |
Verfahren und zusammensetzungen im zusammenhang mit prostatakrebstherapeutika
|
DK3189132T3
(da)
|
2014-09-04 |
2020-08-10 |
Stemcell Tech Inc |
Opløselige antistofkomplekser til T-celle- eller NK-celle-aktivering og -ekspansion
|
EP3925622A1
(de)
|
2014-09-13 |
2021-12-22 |
Novartis AG |
Kombinationstherapien
|
US10759860B2
(en)
|
2014-09-16 |
2020-09-01 |
Synermore Biologics Co., Ltd. |
Anti-EGFR antibody and uses of same
|
WO2016041082A1
(en)
|
2014-09-17 |
2016-03-24 |
CDRD Ventures, Inc. |
Cytotoxic and anti-mitotic compounds, and methods of using the same
|
US20170209574A1
(en)
|
2014-10-03 |
2017-07-27 |
Novartis Ag |
Combination therapies
|
CA2963091A1
(en)
|
2014-10-06 |
2016-04-14 |
Dana-Farber Cancer Institute, Inc. |
Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
|
JP6574257B2
(ja)
|
2014-10-07 |
2019-09-11 |
アン アンド ロバート エイチ. ルーリー チルドレンズ ホスピタル オブ シカゴ |
新規の抗Nodal抗体及びその使用方法
|
CA2963602A1
(en)
|
2014-10-09 |
2016-04-14 |
Dana-Farber Cancer Institute, Inc. |
Multiple-variable il-2 dose regimen for treating immune disorders
|
TWI716362B
(zh)
|
2014-10-14 |
2021-01-21 |
瑞士商諾華公司 |
針對pd-l1之抗體分子及其用途
|
JP6951246B2
(ja)
|
2014-11-05 |
2021-10-20 |
アネクソン,インコーポレーテッド |
ヒト化抗補体因子C1q抗体及びその使用
|
MX2017007136A
(es)
|
2014-12-05 |
2017-12-04 |
Immunext Inc |
Identificacion de vsig8 como el receptor vista putativo y su uso para producir moduladores vista/vsig8.
|
WO2016094273A1
(en)
|
2014-12-08 |
2016-06-16 |
Dana-Farber Cancer Institute, Inc. |
Methods for upregulating immune responses using combinations of anti-rgmb and anti-pd-1 agents
|
US20170340733A1
(en)
|
2014-12-19 |
2017-11-30 |
Novartis Ag |
Combination therapies
|
JP2018504400A
(ja)
|
2015-01-08 |
2018-02-15 |
バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. |
Lingo‐1拮抗薬及び脱髄障害の治療のための使用
|
AU2016206682B2
(en)
|
2015-01-14 |
2021-11-11 |
The Brigham And Women's Hospital, Inc. |
Treatment of cancer with anti-LAP monoclonal antibodies
|
CN107405410B
(zh)
|
2015-01-15 |
2021-08-10 |
OncoQuest制药有限公司 |
增加抗癌剂向靶递送的方法
|
DK3254110T3
(da)
|
2015-02-03 |
2020-05-18 |
Ventana Med Syst Inc |
Histokemisk test til vurdering af ekspression af programmeret død-ligand 1 (pd-l1)
|
CN107249626A
(zh)
|
2015-02-19 |
2017-10-13 |
辉瑞大药厂 |
脑膜炎奈瑟球菌组合物及其方法
|
CA2977499C
(en)
|
2015-02-25 |
2023-10-03 |
Vanderbilt University |
Antibody-mediated neutralization of marburg virus
|
AU2016229238B2
(en)
|
2015-03-06 |
2022-06-02 |
Dana-Farber Cancer Institute, Inc. |
PD-L2 biomarkers predictive of PD-1 pathway inhibitor responses in esophagogastric cancers
|
KR20170125941A
(ko)
|
2015-03-06 |
2017-11-15 |
체에스엘 베링 리컴비넌트 퍼실리티 아게 |
개선된 반감기를 갖는 변형된 폰 빌레브란트 인자
|
JP6782250B2
(ja)
|
2015-03-20 |
2020-11-11 |
ファイザー・インク |
Ctiファーマコフォアを含有する二官能性細胞毒性剤
|
WO2016164358A1
(en)
|
2015-04-06 |
2016-10-13 |
True North Therapeutics, Inc. |
Humanized anti-c1s antibodies and methods of use thereof
|
IL255076B2
(en)
|
2015-04-17 |
2023-10-01 |
Amgen Res Munich Gmbh |
CDH3 and CD3 bispecific antibody constructs
|
US10954515B2
(en)
|
2015-04-21 |
2021-03-23 |
Institut Gustave Roussy |
Therapeutic methods, products and compositions inhibiting ZNF555
|
GB201506869D0
(en)
|
2015-04-22 |
2015-06-03 |
Ucb Biopharma Sprl |
Method
|
GB201506870D0
(en)
|
2015-04-22 |
2015-06-03 |
Ucb Biopharma Sprl |
Method
|
EP3288584A2
(de)
|
2015-04-30 |
2018-03-07 |
President and Fellows of Harvard College |
Anti-ap2-antikörper und antigenbindemittel zur behandlung von stoffwechselerkrankungen
|
GB201508180D0
(en)
|
2015-05-13 |
2015-06-24 |
Ucb Biopharma Sprl |
Antibodies
|
JP6851322B2
(ja)
|
2015-05-27 |
2021-03-31 |
ユーシービー バイオファルマ エスアールエル |
神経疾患を治療する方法
|
CA2989963A1
(en)
|
2015-06-19 |
2016-12-22 |
Cytrx Corporation |
Delivery systems for controlled drug release
|
JP7026509B2
(ja)
|
2015-06-24 |
2022-02-28 |
ヤンセン ファーマシューティカ エヌブイ |
抗vista抗体およびフラグメント
|
JOP20200312A1
(ar)
|
2015-06-26 |
2017-06-16 |
Novartis Ag |
الأجسام المضادة للعامل xi وطرق الاستخدام
|
KR20180025962A
(ko)
|
2015-07-06 |
2018-03-09 |
유씨비 바이오파마 에스피알엘 |
타우 결합 항체
|
TN2017000543A1
(en)
|
2015-07-06 |
2019-04-12 |
Ucb Biopharma Sprl |
Tau-binding antibodies
|
GB201601077D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibody molecule
|
GB201601075D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibodies molecules
|
GB201601073D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibodies
|
US20180222982A1
(en)
|
2015-07-29 |
2018-08-09 |
Novartis Ag |
Combination therapies comprising antibody molecules to pd-1
|
EP3316902A1
(de)
|
2015-07-29 |
2018-05-09 |
Novartis AG |
Kombinationstherapien mit antikörpermolekülen gegen tim-3
|
LT3317301T
(lt)
|
2015-07-29 |
2021-07-26 |
Novartis Ag |
Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3
|
TWI793062B
(zh)
|
2015-07-31 |
2023-02-21 |
德商安美基研究(慕尼黑)公司 |
Dll3及cd3抗體構築體
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究(慕尼黑)公司 |
Flt3及cd3抗體構築體
|
TWI717375B
(zh)
|
2015-07-31 |
2021-02-01 |
德商安美基研究(慕尼黑)公司 |
Cd70及cd3抗體構築體
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究(慕尼黑)公司 |
Egfrviii及cd3抗體構築體
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究(慕尼黑)公司 |
Msln及cd3抗體構築體
|
EP3331536A4
(de)
|
2015-08-03 |
2019-03-27 |
The Regents of The University of California |
Zusammensetzungen und verfahren zur modulierung der abhd2-aktivität
|
EP3331918A1
(de)
|
2015-08-04 |
2018-06-13 |
GlaxoSmithKline Intellectual Property Development Limited |
Kombinationsbehandlungen und verwendungen und verfahren dafür
|
US20180222990A1
(en)
|
2015-08-04 |
2018-08-09 |
Glaxosmithkline Intellectual Property Development Limited |
Combination Treatments and Uses and Methods Thereof
|
WO2017021910A1
(en)
|
2015-08-04 |
2017-02-09 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatments and uses and methods thereof
|
BR112018002520A2
(pt)
|
2015-08-06 |
2018-09-18 |
Glaxosmithkline Ip Dev Ltd |
Agonistas de tlr4 e composições dos mesmos e seuuso no tratamento de câncer
|
TW201716084A
(zh)
|
2015-08-06 |
2017-05-16 |
葛蘭素史克智慧財產發展有限公司 |
組合物及其用途與治療
|
WO2017021912A1
(en)
|
2015-08-06 |
2017-02-09 |
Glaxosmithkline Intellectual Property Development Limited |
Combined tlrs modulators with anti ox40 antibodies
|
WO2017031353A1
(en)
|
2015-08-19 |
2017-02-23 |
Rutgers, The State University Of New Jersey |
Novel methods of generating antibodies
|
KR20180042412A
(ko)
|
2015-09-02 |
2018-04-25 |
이뮤텝 에스.에이.에스. |
항-lag-3 항체
|
CN116063481A
(zh)
|
2015-09-04 |
2023-05-05 |
普里玛托普医疗股份有限公司 |
人源化抗-cd40抗体及其用途
|
KR20230155021A
(ko)
|
2015-09-15 |
2023-11-09 |
스칼러 락, 인크. |
항-프로/잠재성-미오스타틴 항체 및 그의 용도
|
US10738334B2
(en)
|
2015-09-23 |
2020-08-11 |
Pfizer Inc. |
Cells having reduced BCAT1
|
CA3000531A1
(en)
|
2015-10-07 |
2017-04-13 |
Obi Pharma, Inc. |
Novel carbohydrate antibodies, pharmaceutical compositions and uses thereof
|
US11161912B2
(en)
|
2015-10-13 |
2021-11-02 |
Technion Research & Development Foundation Limited |
Heparanase-neutralizing monoclonal antibodies
|
WO2017066561A2
(en)
|
2015-10-16 |
2017-04-20 |
President And Fellows Of Harvard College |
Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
|
WO2017072183A1
(en)
|
2015-10-27 |
2017-05-04 |
Ucb Biopharma Sprl |
Methods of treatment using anti-il-17a/f antibodies
|
WO2017075329A2
(en)
|
2015-10-29 |
2017-05-04 |
Dana-Farber Cancer Institute, Inc. |
Methods for identification, assessment, prevention, and treatment of metabolic disorders using pm20d1 and n-lipidated amino acids
|
BR112018008799A2
(pt)
|
2015-10-30 |
2019-01-15 |
Glaxosmithkline Ip Dev Ltd |
método de prognóstico
|
CN107043406B
(zh)
|
2015-11-03 |
2021-08-17 |
财团法人工业技术研究院 |
化合物、连接子-药物、及配体-药物耦合体
|
US20180320136A1
(en)
|
2015-11-03 |
2018-11-08 |
GlycoMimitics, Inc. |
Methods and compositions for the production of monoclonal antibodies, hematopoietic stem cells, and methods of using the same
|
CA3004438A1
(en)
|
2015-11-09 |
2017-05-18 |
The Children's Hospital Of Philadelphia |
Glypican 2 as a cancer marker and therapeutic target
|
KR20180101341A
(ko)
|
2015-11-10 |
2018-09-12 |
비스테라, 인크. |
리포폴리사카라이드에 특이적으로 결합하는 항체 분자-약물 접합체 및 그의 용도
|
SI3380522T1
(sl)
|
2015-11-25 |
2024-02-29 |
Visterra, Inc. |
Molekule protitelesa proti APRIL in uporabe le-teh
|
WO2017093942A1
(en)
|
2015-12-01 |
2017-06-08 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatments and uses and methods thereof
|
GB201521389D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Method
|
GB201521382D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
GB201521383D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl And Ucb Celltech |
Method
|
GB201521391D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
GB201521393D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
WO2017096311A1
(en)
|
2015-12-04 |
2017-06-08 |
Seattle Genetics, Inc. |
Conjugates of quaternized tubulysin compounds
|
US11793880B2
(en)
|
2015-12-04 |
2023-10-24 |
Seagen Inc. |
Conjugates of quaternized tubulysin compounds
|
US20180371093A1
(en)
|
2015-12-17 |
2018-12-27 |
Novartis Ag |
Antibody molecules to pd-1 and uses thereof
|
RU2018125603A
(ru)
|
2015-12-17 |
2020-01-21 |
Новартис Аг |
Комбинация ингибитора с-мет с молекулой антитела к pd-1 и ее применения
|
WO2017106806A1
(en)
|
2015-12-18 |
2017-06-22 |
Federica Cavallo |
COMPOSITIONS AND METHODS RELATED TO xCT PEPTIDES
|
GB201522394D0
(en)
|
2015-12-18 |
2016-02-03 |
Ucb Biopharma Sprl |
Antibodies
|
EP3184544A1
(de)
|
2015-12-23 |
2017-06-28 |
Julius-Maximilians-Universität Würzburg |
Glycoprotein-v-inhibitoren zur verwendung als koagulansien
|
WO2017120523A2
(en)
|
2016-01-08 |
2017-07-13 |
Scholar Rock, Inc. |
Anti-pro/latent myostatin antibodies and methods of use thereof
|
WO2017134547A1
(en)
|
2016-02-01 |
2017-08-10 |
Pfizer Inc. |
Tubulysin analogs and methods for their preparation
|
MD3411402T2
(ro)
|
2016-02-03 |
2022-05-31 |
Amgen Res Munich Gmbh |
Constructe de anticorpi bispecifici BCMA și CD3 de angajare a celulei T
|
EA039859B1
(ru)
|
2016-02-03 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
TN2018000266A1
(en)
|
2016-02-03 |
2020-01-16 |
Amgen Res Munich Gmbh |
Psma and cd3 bispecific t cell engaging antibody constructs.
|
EP3410849B1
(de)
|
2016-02-05 |
2023-07-05 |
Institut Pasteur |
Verwendung von inhibitoren von adam12 als adjuvanzien in tumortherapien
|
TW202216201A
(zh)
|
2016-02-12 |
2022-05-01 |
比利時商楊森製藥公司 |
抗vista抗體及片段、其用途及鑑定其之方法
|
EP3207937A1
(de)
|
2016-02-17 |
2017-08-23 |
Royal College of Surgeons in Ireland |
Verfahren zur behandlung oder prävention von sepsis
|
JP2019509282A
(ja)
|
2016-02-29 |
2019-04-04 |
ファウンデーション・メディシン・インコーポレイテッド |
癌の治療方法
|
EP4043492A1
(de)
|
2016-03-01 |
2022-08-17 |
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. |
Gegen humanen poliovirus-rezeptor (pvr) spezifische antikörper
|
WO2017156263A1
(en)
|
2016-03-09 |
2017-09-14 |
Memorial Sloan-Kettering Cancer Center |
Enigma and cdh18 as companion diagnostics for cdk4 inhibitors
|
AU2017229991A1
(en)
|
2016-03-10 |
2018-10-04 |
Aperisys, Inc. |
Antigen-binding fusion proteins with modified HSP70 domains
|
JP2019509737A
(ja)
|
2016-03-11 |
2019-04-11 |
スカラー ロック インコーポレイテッドScholar Rock,Inc. |
TGFβ1結合性免疫グロブリンおよびその使用
|
TN2018000301A1
(en)
|
2016-03-14 |
2020-01-16 |
Univ Oslo |
Engineered immunoglobulins with altered fcrn binding
|
WO2017158421A1
(en)
|
2016-03-14 |
2017-09-21 |
University Of Oslo |
Anti-viral engineered immunoglobulins
|
JP7049311B2
(ja)
|
2016-03-17 |
2022-04-06 |
ヌマブ イノヴェイション アーゲー |
抗TNFα抗体およびそれらの機能的断片
|
EP3430042B1
(de)
|
2016-03-17 |
2023-05-24 |
Numab Innovation AG |
Anti-tnf-alpha-antikörper und funktionale fragmente davon
|
WO2017158436A1
(en)
|
2016-03-17 |
2017-09-21 |
Oslo Universitetssykehus Hf |
Fusion proteins targeting tumour associated macrophages for treating cancer
|
WO2017158101A1
(en)
|
2016-03-17 |
2017-09-21 |
Numab Innovation Ag |
ANTI-TNFα-ANTIBODIES AND FUNCTIONAL FRAGMENTS THEREOF
|
PT3219727T
(pt)
|
2016-03-17 |
2021-01-21 |
Tillotts Pharma Ag |
Anticorpos anti-tnf alfa e fragmentos funcionais dos mesmos
|
DK3219726T3
(da)
|
2016-03-17 |
2020-12-07 |
Tillotts Pharma Ag |
Anti-TNF-alfa-antistoffer og funktionelle fragmenter deraf
|
CN109153728A
(zh)
|
2016-03-21 |
2019-01-04 |
埃尔斯塔治疗公司 |
多特异性和多功能分子及其用途
|
JP7073266B2
(ja)
|
2016-03-25 |
2022-05-23 |
シージェン インコーポレイテッド |
Peg化薬物リンカー及びその中間体を調製するためのプロセス
|
TW202302144A
(zh)
|
2016-03-25 |
2023-01-16 |
美商威特拉公司 |
登革病毒的抗體分子之配方設計
|
IL311675A
(en)
|
2016-04-04 |
2024-05-01 |
Bioverativ Usa Inc |
Anti-complement factor BB antibodies and their uses
|
SG11201808356UA
(en)
|
2016-04-05 |
2018-10-30 |
Pfizer |
Cell culture process
|
EP3439692A4
(de)
|
2016-04-08 |
2020-01-22 |
ITI Health, Inc. |
Plectin-1-antikörper und verwendungen davon
|
WO2017181098A2
(en)
|
2016-04-15 |
2017-10-19 |
Visterra, Inc. |
Antibody molecules to zika virus and uses thereof
|
RU2021111187A
(ru)
|
2016-04-15 |
2021-04-29 |
Янссен Фармасьютикалз, Инк. |
Антитела против человеческого vista и их применение
|
JOP20170091B1
(ar)
|
2016-04-19 |
2021-08-17 |
Amgen Res Munich Gmbh |
إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
|
CA3024027A1
(en)
|
2016-05-11 |
2017-11-16 |
Amgen Inc. |
Direct selection of cells expressing high levels of heteromeric proteins using glutamine synthetase intragenic complementation vectors
|
WO2017197045A1
(en)
|
2016-05-11 |
2017-11-16 |
Movassaghi Mohammad |
Convergent and enantioselective total synthesis of communesin analogs
|
TW201802121A
(zh)
|
2016-05-25 |
2018-01-16 |
諾華公司 |
抗因子XI/XIa抗體之逆轉結合劑及其用途
|
WO2017203051A1
(en)
|
2016-05-26 |
2017-11-30 |
University College Cork - National University Of Ireland, Cork |
An engineered gram positive bacterium
|
US11534496B2
(en)
|
2016-06-07 |
2022-12-27 |
The Brigham And Women's Hospital, Inc. |
Compositions and methods relating to T peripheral helper cells in autoantibody-associated conditions
|
GB201610198D0
(en)
|
2016-06-10 |
2016-07-27 |
Ucb Biopharma Sprl |
Anti-ige antibodies
|
EP3472210A1
(de)
|
2016-06-17 |
2019-04-24 |
Life Technologies Corporation |
Stellenspezifische vernetzung von antikörpern
|
WO2017221072A2
(en)
|
2016-06-21 |
2017-12-28 |
University Of Oslo |
Hla binding vaccine moieties and uses thereof
|
MA45668A
(fr)
|
2016-07-13 |
2019-05-22 |
Biogen Ma Inc |
Schémas posologiques d'antagonistes de lingo-1 et leurs utilisations pour le traitement de troubles de démyélinisation
|
CN109641947B
(zh)
|
2016-07-20 |
2023-04-14 |
犹他大学研究基金会 |
Cd229 car t细胞及其使用方法
|
EP3494134A1
(de)
|
2016-08-02 |
2019-06-12 |
Visterra, Inc. |
Manipulierte polypeptide und verwendungen davon
|
JP2018058822A
(ja)
|
2016-08-03 |
2018-04-12 |
ファイザー・インク |
ヘテロアリールスルホンをベースとするコンジュゲーションハンドル、これらの調製のための方法、および抗体薬物コンジュゲートの合成におけるこれらの使用
|
MA45945A
(fr)
|
2016-08-09 |
2019-06-19 |
Seattle Genetics Inc |
Conjugués de médicaments avec des lieurs auto-stabilisants, aux propriétés physiochimiques améliorées
|
MA45934A
(fr)
|
2016-08-10 |
2019-06-19 |
Centre Nat Rech Scient |
Procédés et réactifs utilisés pour la détection du paludisme à plasmodium falciparum résistant à la pipéraquine
|
PL3497132T3
(pl)
|
2016-08-15 |
2020-11-30 |
Novartis Ag |
Schematy i sposoby leczenia stwardnienia rozsianego z zastosowaniem ofatumumabu
|
WO2018038684A1
(en)
|
2016-08-26 |
2018-03-01 |
Agency For Science, Technology And Research |
Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof
|
EP3293271A1
(de)
|
2016-09-12 |
2018-03-14 |
The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin |
Marker und target als eine diagnosevariable und target zur therapie von metastatischem krebs
|
WO2018057618A1
(en)
|
2016-09-20 |
2018-03-29 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for identification, assessment, prevention, and treatment of aml using usp10 biomarkers and modulators
|
CN118005799A
(zh)
|
2016-09-23 |
2024-05-10 |
马伦戈治疗公司 |
包含λ轻链和κ轻链的多特异性抗体分子
|
MA46359A
(fr)
|
2016-09-29 |
2019-08-07 |
Amgen Inc |
Protéines de liaison à l'antigène à viscosité faible et leurs procédés de préparation
|
GB201616596D0
(en)
|
2016-09-29 |
2016-11-16 |
Nascient Limited |
Epitope and antibodies
|
IL265957B2
(en)
|
2016-10-12 |
2024-04-01 |
Bioverativ Usa Inc |
Anti-C1S antibodies and methods of using them
|
MA46660A
(fr)
|
2016-10-18 |
2019-08-28 |
Seattle Genetics Inc |
Administration ciblée d'inhibiteurs de la voie de récupération de nicotinamide adénine dinucléotide
|
JP2020500878A
(ja)
|
2016-12-01 |
2020-01-16 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
併用療法
|
EP3548068A1
(de)
|
2016-12-01 |
2019-10-09 |
GlaxoSmithKline Intellectual Property Development Limited |
Kombinationstherapie
|
JP7244987B2
(ja)
|
2016-12-14 |
2023-03-23 |
シージェン インコーポレイテッド |
多剤抗体薬物コンジュゲート
|
CN110300761B
(zh)
|
2016-12-15 |
2023-05-09 |
国家生物技术研究所公司 |
抗pcna单克隆抗体及其用途
|
GB201621635D0
(en)
|
2016-12-19 |
2017-02-01 |
Ucb Biopharma Sprl |
Crystal structure
|
CN118047864A
(zh)
|
2016-12-23 |
2024-05-17 |
百时美施贵宝公司 |
用于改进生物分析和生物加工特性的治疗性免疫球蛋白g4的设计
|
US11820979B2
(en)
|
2016-12-23 |
2023-11-21 |
Visterra, Inc. |
Binding polypeptides and methods of making the same
|
KR102616666B1
(ko)
|
2016-12-23 |
2023-12-27 |
노파르티스 아게 |
인자 xi 항체 및 사용 방법
|
SI3565592T1
(sl)
|
2017-01-06 |
2023-05-31 |
Scholar Rock, Inc. |
Zdravljenje presnovnih bolezni z zaviranjem aktivacije miostatina
|
PT3565592T
(pt)
|
2017-01-06 |
2023-05-31 |
Scholar Rock Inc |
Tratamento de doenças metabólicas através da inibição da ativação da miostatina
|
CN117398457A
(zh)
|
2017-01-06 |
2024-01-16 |
供石公司 |
亚型特异性、背景许可性TGFβ1抑制剂及其用途
|
EP3568411B1
(de)
|
2017-01-13 |
2024-03-06 |
Pietro P. Sanna |
Verfahren und zusammensetzungen zur behandlung von hpa-hyperaktivität
|
AU2018209940A1
(en)
|
2017-01-18 |
2019-07-11 |
Visterra, Inc. |
Antibody molecule-drug conjugates and uses thereof
|
CN110461860A
(zh)
|
2017-01-24 |
2019-11-15 |
辉瑞公司 |
卡奇霉素衍生物及其抗体药物缀合物
|
SG11201906519RA
(en)
|
2017-01-31 |
2019-08-27 |
Pfizer |
Neisseria meningitidis compositions and methods thereof
|
JOP20190189A1
(ar)
|
2017-02-02 |
2019-08-01 |
Amgen Res Munich Gmbh |
تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
|
US20180221476A1
(en)
|
2017-02-06 |
2018-08-09 |
Oncoquest Nc. |
Treatment of cancer with therapeutic monoclonal antibody specific for a tumor associated antigen and an immune adjuvant
|
US20190375847A1
(en)
|
2017-02-15 |
2019-12-12 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatment for cancer
|
US20200291089A1
(en)
|
2017-02-16 |
2020-09-17 |
Elstar Therapeutics, Inc. |
Multifunctional molecules comprising a trimeric ligand and uses thereof
|
JP7116736B2
(ja)
|
2017-03-02 |
2022-08-10 |
ノバルティス アーゲー |
操作されたヘテロ二量体タンパク質
|
WO2018165649A1
(en)
|
2017-03-10 |
2018-09-13 |
Embera Neurotherapeutics, Inc. |
Pharmaceutical compositions and uses thereof
|
JP7293122B2
(ja)
|
2017-03-14 |
2023-06-19 |
バイオベラティブ・ユーエスエイ・インコーポレイテッド |
補体が媒介する疾患および障害を処置するための方法
|
US20200010528A1
(en)
|
2017-03-15 |
2020-01-09 |
Cue Biopharma, Inc. |
Methods for modulating an immune response
|
CA3056182A1
(en)
|
2017-03-16 |
2018-09-20 |
Pfizer Inc. |
Tyrosine prototrophy
|
IL269398B2
(en)
|
2017-03-24 |
2024-05-01 |
Seagen Inc |
A process for the preparation of glucuronide-drug binders and their intermediates
|
EP3599843A4
(de)
|
2017-03-24 |
2021-01-13 |
The Regents of the University of California |
Proteoglycan-irregularitäten in abnormalen fibroblasten und darauf basierende therapien
|
WO2018183366A1
(en)
|
2017-03-28 |
2018-10-04 |
Syndax Pharmaceuticals, Inc. |
Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy
|
KR20200020662A
(ko)
|
2017-04-03 |
2020-02-26 |
온콜로지, 인크. |
면역-종양학 제제와 함께 ps-표적화 항체를 사용하여 암을 치료하는 방법
|
US20200071417A1
(en)
|
2017-04-19 |
2020-03-05 |
Elstar Therapeutics, Inc. |
Multispecific molecules and uses thereof
|
CN110799529A
(zh)
|
2017-04-22 |
2020-02-14 |
免疫治疗有限公司 |
改良lamp构建物
|
MA51189A
(fr)
|
2017-04-27 |
2020-03-04 |
Seattle Genetics Inc |
Conjugués d'inhibiteur de la voie de récupération du nicotinamide adénine dinucléotide quaternarisé
|
EP3615065A1
(de)
|
2017-04-28 |
2020-03-04 |
Amgen Inc. |
Hilfsstoffe zur verringerung der viskosität von antikörperformulierungen und formulierungszusammensetzungen
|
AU2018260545B2
(en)
|
2017-04-28 |
2023-11-23 |
Marengo Therapeutics, Inc. |
Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
|
US20200179511A1
(en)
|
2017-04-28 |
2020-06-11 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
IL297073B2
(en)
|
2017-05-02 |
2023-12-01 |
Immunomic Therapeutics Inc |
LAMP constructs containing cancer antigens
|
BR112019022751A2
(pt)
|
2017-05-05 |
2020-05-19 |
Amgen Inc |
composição farmacêutica compreendendo construtos de anticorpos biespecíficos para armazenamento e administração melhorados
|
EP3624848A1
(de)
|
2017-05-19 |
2020-03-25 |
Syndax Pharmaceuticals, Inc. |
Kombinationstherapien
|
CN110753703B
(zh)
|
2017-05-23 |
2024-04-09 |
德国亥姆霍兹慕尼黑中心健康与环境研究中心(有限公司) |
新的cd73抗体、其制备和用途
|
KR102344616B1
(ko)
|
2017-05-30 |
2021-12-31 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 오클라호마 |
항-더블코르틴-유사 키나제 1 항체 및 사용 방법
|
WO2018222901A1
(en)
|
2017-05-31 |
2018-12-06 |
Elstar Therapeutics, Inc. |
Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
|
EP3634496A4
(de)
|
2017-06-06 |
2021-09-08 |
Dana-Farber Cancer Institute, Inc. |
Verfahren zur sensibilisierung von krebszellen gegen t-zell-vermittelte abtötung mittels modulierung von molekularen signalwegen
|
US11325957B2
(en)
|
2017-06-19 |
2022-05-10 |
Cell Design Labs, Inc. |
Methods and compositions for reducing the immunogenicity of chimeric notch receptors
|
CN110785187B
(zh)
|
2017-06-22 |
2024-04-05 |
诺华股份有限公司 |
针对cd73的抗体分子及其用途
|
EP3642240A1
(de)
|
2017-06-22 |
2020-04-29 |
Novartis AG |
Antikörpermoleküle gegen cd73 und verwendungen davon
|
US20200223924A1
(en)
|
2017-06-27 |
2020-07-16 |
Novartis Ag |
Dosage regimens for anti-tim-3 antibodies and uses thereof
|
WO2019005503A1
(en)
|
2017-06-29 |
2019-01-03 |
Rutgers, The State University Of New Jersey |
COMPOSITIONS AND METHODS TARGETING G12 SIGNALING FOR BRONCHODILATORY THERAPY
|
EP3431496A1
(de)
|
2017-07-19 |
2019-01-23 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Anti-isoasp7-amyloid-beta-antikörper und verwendungen davon
|
KR20200031659A
(ko)
|
2017-07-20 |
2020-03-24 |
노파르티스 아게 |
항-lag-3 항체의 투여 요법 및 그의 용도
|
WO2019023661A1
(en)
|
2017-07-28 |
2019-01-31 |
Scholar Rock, Inc. |
SPECIFIC INHIBITORS OF TGF-BETA 1 LTBP COMPLEX AND USES THEREOF
|
JP6889328B2
(ja)
|
2017-07-31 |
2021-06-18 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
三次元構造に基づくヒト化方法
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
CA3075717A1
(en)
|
2017-09-14 |
2019-03-21 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatment for cancer
|
JP2020533382A
(ja)
|
2017-09-14 |
2020-11-19 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
癌の組合せ治療
|
CN111107874A
(zh)
|
2017-09-14 |
2020-05-05 |
葛兰素史密斯克莱知识产权发展有限公司 |
用于癌症的组合治疗
|
JP2020533983A
(ja)
|
2017-09-15 |
2020-11-26 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
目的のポリペプチドのラージスケールの製造間のオンラインバイオマス静電容量モニタリング
|
LT3681483T
(lt)
|
2017-09-15 |
2022-09-12 |
Amgen Inc. |
Terapinio baltymo farmacinės formos liofilizavimo būdas
|
EP3461841B1
(de)
|
2017-10-02 |
2019-09-11 |
Certest Biotec, S.L. |
Antikörper gegen dps und testvorrichtungen zum nachweis von bakterien der gattung campylobacter
|
SG11202002248TA
(en)
|
2017-10-02 |
2020-04-29 |
Visterra Inc |
Antibody molecules to cd138 and uses thereof
|
US10640508B2
(en)
|
2017-10-13 |
2020-05-05 |
Massachusetts Institute Of Technology |
Diazene directed modular synthesis of compounds with quaternary carbon centers
|
BR112020007046A2
(pt)
|
2017-10-19 |
2020-11-17 |
Debiopharm International S.A. |
produto de combinação para o tratamento do câncer
|
WO2019077165A1
(en)
|
2017-10-20 |
2019-04-25 |
Institut Curie |
DAP10 / 12-BASED CHIMERIC ANTIGENIC RECEPTORS (CAR) ADAPTED FOR RUSH
|
EP3697811A1
(de)
|
2017-10-20 |
2020-08-26 |
Institut Curie |
Hakenfusionsprotein zur regulierung der zellulären transportsteuerung eines zielproteins
|
EP3706795A4
(de)
|
2017-11-09 |
2021-10-13 |
Pinteon Therapeutics Inc. |
Verfahren und zusammensetzungen zur erzeugung und verwendung von humanisierten konformationsspezifischen phosphorylierten tau-antikörpern
|
KR20200089286A
(ko)
|
2017-11-16 |
2020-07-24 |
노파르티스 아게 |
조합 요법
|
MX2020005658A
(es)
|
2017-11-30 |
2020-11-11 |
Centurion Biopharma Corp |
Profarmacos de union a albumina de derivados de auristatina e.
|
US11572373B2
(en)
|
2017-11-30 |
2023-02-07 |
Ladrx Corporation |
Maytansinoid-based drug delivery systems
|
WO2019106605A1
(en)
|
2017-12-01 |
2019-06-06 |
Board Of Regents, The University Of Texas System |
Combination treatment for cancer
|
WO2019113464A1
(en)
|
2017-12-08 |
2019-06-13 |
Elstar Therapeutics, Inc. |
Multispecific molecules and uses thereof
|
EA202091422A1
(ru)
|
2017-12-11 |
2020-08-28 |
Эмджен Инк. |
Способ непрерывного производства продуктов на основе биспецифических антител
|
TW201940518A
(zh)
|
2017-12-29 |
2019-10-16 |
美商安進公司 |
針對muc17和cd3之雙特異性抗體構建體
|
US20210251899A1
(en)
|
2018-01-25 |
2021-08-19 |
Acm Biolabs Pte Ltd |
Polymersomes comprising a soluble encapsulated antigen as well as methods of making and uses thereof
|
WO2019150309A1
(en)
|
2018-02-02 |
2019-08-08 |
Hammack Scott |
Modulators of gpr68 and uses thereof for treating and preventing diseases
|
US11834487B2
(en)
|
2018-02-12 |
2023-12-05 |
Hadasit Medical Research Services & Development Ltd. |
Modulation of SLAMF6 splice variants for cancer therapy
|
GB201802486D0
(en)
|
2018-02-15 |
2018-04-04 |
Ucb Biopharma Sprl |
Methods
|
CN111989339A
(zh)
|
2018-02-20 |
2020-11-24 |
西雅图基因公司 |
疏水性奥瑞他汀f化合物及其缀合物
|
CA3092037A1
(en)
|
2018-02-21 |
2019-08-29 |
Celgene Corporation |
Bcma-binding antibodies and uses thereof
|
EP3755712A1
(de)
|
2018-02-21 |
2020-12-30 |
Cell Design Labs, Inc. |
Chimäre transmembranrezeptoren und verwendungen davon
|
EP3530282A1
(de)
|
2018-02-27 |
2019-08-28 |
Diaccurate |
Therapeutische verfahren
|
WO2019178362A1
(en)
|
2018-03-14 |
2019-09-19 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
US20210009711A1
(en)
|
2018-03-14 |
2021-01-14 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
EP3765076A1
(de)
|
2018-03-16 |
2021-01-20 |
Bristol-Myers Squibb Company |
Reduktion der metabolischen enzymaktivität und der disulfidbindung während der proteinherstellung
|
JP2021519443A
(ja)
|
2018-03-26 |
2021-08-10 |
グリカノスティックス エス・アール・オーGlycanostics S.R.O. |
タンパク質糖鎖プロファイリングの手段及び方法
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
EP3785732A4
(de)
|
2018-04-24 |
2022-02-23 |
Ampsource Biopharma Shanghai Inc. |
Antikörper gegen tim-3 und anwendung davon
|
AU2019264965A1
(en)
|
2018-05-09 |
2020-11-19 |
Nectin Therapeutics Ltd. |
Antibodies specific to human Nectin4
|
JP2021523185A
(ja)
|
2018-05-15 |
2021-09-02 |
イミュノミック セラピューティックス, インコーポレイテッドImmunomic Therapeutics, Inc. |
アレルゲンを含む改善されたlamp構築物
|
CA3101553A1
(en)
|
2018-05-31 |
2019-12-05 |
Glaxosmithkline Intellectual Property Development Limited |
Combination of a type ii protein arginine methyltransferase inhibitor and an icos binding protein to treat cancer
|
WO2019232244A2
(en)
|
2018-05-31 |
2019-12-05 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
JP2021525271A
(ja)
|
2018-05-31 |
2021-09-24 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
Icos結合タンパク質及びアルギニンメチルトランスフェラーゼ阻害剤を用いた複合療法
|
WO2019236417A1
(en)
|
2018-06-04 |
2019-12-12 |
Biogen Ma Inc. |
Anti-vla-4 antibodies having reduced effector function
|
JP2021526014A
(ja)
|
2018-06-05 |
2021-09-30 |
アムジエン・インコーポレーテツド |
抗体依存性細胞貪食の調節
|
TW202015740A
(zh)
|
2018-06-07 |
2020-05-01 |
美商西雅圖遺傳學公司 |
喜樹鹼結合物
|
CA3104295A1
(en)
|
2018-06-19 |
2019-12-26 |
Atarga, Llc |
Antibody molecules to complement component 5 and uses thereof
|
WO2019244107A1
(en)
|
2018-06-21 |
2019-12-26 |
Daiichi Sankyo Company, Limited |
Compositions including cd3 antigen binding fragments and uses thereof
|
AU2019297451A1
(en)
|
2018-07-03 |
2021-01-28 |
Marengo Therapeutics, Inc. |
Anti-TCR antibody molecules and uses thereof
|
WO2020008083A1
(es)
|
2018-07-05 |
2020-01-09 |
Consejo Superior De Investigaciones Científicas |
Diana terapéutica en receptores de quimiocinas para la selección de compuestos útiles para el tratamiento de procesos patológicos que implican la señalización de quimiocinas
|
EP3820896A1
(de)
|
2018-07-11 |
2021-05-19 |
Scholar Rock, Inc. |
Tgfbeta1-inhibitoren und verwendung davon
|
RS62914B1
(sr)
|
2018-07-11 |
2022-03-31 |
Scholar Rock Inc |
Izoform selektivni inhibitori tgfbeta1 i njihova upotreba
|
CA3105988A1
(en)
|
2018-07-11 |
2020-01-16 |
Abhishek Datta |
High-affinity, isoform-selective tgf.beta.1 inhibitors and use thereof
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
JP2021532140A
(ja)
|
2018-07-30 |
2021-11-25 |
アムジェン リサーチ (ミュニック) ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Cd33及びcd3に結合する二重特異性抗体コンストラクトの長期投与
|
AU2019314999A1
(en)
|
2018-08-03 |
2021-02-11 |
Amgen Inc. |
Antibody constructs for CLDN18.2 and CD3
|
WO2020030571A1
(en)
|
2018-08-06 |
2020-02-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combinations of a pd-1 antibody and a tlr4 modulator and uses thereof
|
WO2020031087A1
(en)
|
2018-08-06 |
2020-02-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapy
|
WO2020030570A1
(en)
|
2018-08-06 |
2020-02-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combinations of an ox40 antibody and a tlr4 modulator and uses thereof
|
MX2021002332A
(es)
|
2018-08-27 |
2021-08-11 |
Affimed Gmbh |
Células nk crioreservadas precargadas con una construcción de anticuerpo.
|
US20220033511A1
(en)
|
2018-09-11 |
2022-02-03 |
Amgen Inc. |
Methods of modulating antibody-dependent cell-mediated cytotoxicity
|
WO2020053325A1
(en)
|
2018-09-12 |
2020-03-19 |
Acm Biolabs Pte Ltd |
Polymersomes comprising a covalently bound antigen as well as methods of making and uses thereof
|
WO2020053808A1
(en)
|
2018-09-12 |
2020-03-19 |
Georg Dewald |
Method of diagnosing vasoregulatory disorders
|
JP7465272B2
(ja)
|
2018-09-27 |
2024-04-10 |
マレンゴ・セラピューティクス,インコーポレーテッド |
Csf1r/ccr2多特異性抗体
|
AR116548A1
(es)
|
2018-09-28 |
2021-05-19 |
Amgen Inc |
Anticuerpos contra bcma soluble
|
AU2019354101A1
(en)
|
2018-10-05 |
2021-04-15 |
Bavarian Nordic A/S |
Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an immune checkpoint antagonist or agonist
|
AU2019356564A1
(en)
|
2018-10-11 |
2021-04-29 |
Amgen Inc. |
Downstream processing of bispecific antibody constructs
|
US20220144941A1
(en)
|
2018-10-16 |
2022-05-12 |
UCB Biopharma SRL |
Method for the treatment of myasthenia gravis
|
JP2022513374A
(ja)
|
2018-10-22 |
2022-02-07 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド |
投薬
|
SG11202104010PA
(en)
|
2018-10-23 |
2021-05-28 |
Scholar Rock Inc |
Rgmc-selective inhibitors and use thereof
|
WO2020089794A1
(en)
|
2018-10-31 |
2020-05-07 |
Glaxosmithkline Intellectual Property Development Limited |
Methods of treating cancer
|
JP2022507744A
(ja)
|
2018-11-20 |
2022-01-18 |
バヴァリアン・ノルディック・アクティーゼルスカブ |
4-1bbl(cd137l)及び/またはcd40lをコードする組み換えmvaの腫瘍内及び/または静脈内投与によって、がんを治療する療法
|
WO2020115655A1
(en)
|
2018-12-06 |
2020-06-11 |
Pfizer Inc. |
Cells with reduced inhibitor production and methods of use thereof
|
WO2020128898A1
(en)
|
2018-12-20 |
2020-06-25 |
Novartis Ag |
Pharmaceutical combinations
|
CN113301954A
(zh)
|
2019-01-13 |
2021-08-24 |
耶路撒冷希伯来大学伊森姆研究发展有限公司 |
特异性针对人类连接蛋白-2的抗体
|
EP3689905A3
(de)
|
2019-01-30 |
2021-02-24 |
Scholar Rock, Inc. |
Ltbp-komplex-spezifische inhibitoren von tgf-beta und verwendungen davon
|
AU2020214412A1
(en)
|
2019-02-01 |
2021-08-12 |
Glaxosmithkline Intellectual Property Development Limited |
Belantamab mafodotin in combination with pembrolizumab for treating cancer
|
EP3693063A1
(de)
|
2019-02-06 |
2020-08-12 |
Diaccurate |
Verfahren und zusammensetzungen zur behandlung von krebs
|
EP3924739A1
(de)
|
2019-02-12 |
2021-12-22 |
Biogen MA Inc. |
Biomarker von progressiver multifokaler leukoenzephalopathie
|
WO2020168059A1
(en)
|
2019-02-15 |
2020-08-20 |
Integral Molecular, Inc. |
Claudin 6 antibodies and uses thereof
|
US10871640B2
(en)
|
2019-02-15 |
2020-12-22 |
Perkinelmer Cellular Technologies Germany Gmbh |
Methods and systems for automated imaging of three-dimensional objects
|
US11254736B2
(en)
|
2019-02-15 |
2022-02-22 |
Integral Molecular, Inc. |
Antibodies comprising a common light chain and uses thereof
|
TWI756633B
(zh)
|
2019-02-15 |
2022-03-01 |
大陸商上海藥明生物技術有限公司 |
具有改善的同質性的抗體-藥物綴合物、其藥物組合物、用途和製備方法
|
AU2020226904A1
(en)
|
2019-02-21 |
2021-09-16 |
Marengo Therapeutics, Inc. |
Anti-TCR antibody molecules and uses thereof
|
JP2022522662A
(ja)
|
2019-02-21 |
2022-04-20 |
マレンゴ・セラピューティクス,インコーポレーテッド |
T細胞に結合する多機能性分子および自己免疫障害を処置するためのその使用
|
JP2022521750A
(ja)
|
2019-02-21 |
2022-04-12 |
マレンゴ・セラピューティクス,インコーポレーテッド |
カルレティキュリンに結合する多機能性分子およびその使用
|
JP2022521937A
(ja)
|
2019-02-21 |
2022-04-13 |
マレンゴ・セラピューティクス,インコーポレーテッド |
NKp30に結合する抗体分子およびその使用
|
CA3130754A1
(en)
|
2019-02-21 |
2020-08-27 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to t cell related cancer cells and uses thereof
|
CN113677708A
(zh)
|
2019-03-26 |
2021-11-19 |
亚狮康私人有限公司 |
采用抗il13r抗体或其结合片段的治疗
|
AU2020253833A1
(en)
|
2019-03-29 |
2021-10-28 |
Atarga, Llc |
Anti FGF23 antibody
|
MA55529A
(fr)
|
2019-04-03 |
2022-02-09 |
Genzyme Corp |
Polypeptides de liaison anti-alpha bêta tcr à fragmentation réduite
|
WO2020208572A1
(en)
|
2019-04-10 |
2020-10-15 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapy with an anti bcma antibody and a gamma secretase inhibitor
|
CN114007642A
(zh)
|
2019-04-30 |
2022-02-01 |
森迪生物科学公司 |
嵌合受体及其使用方法
|
US20220289854A1
(en)
|
2019-04-30 |
2022-09-15 |
Dana-Farber Cancer Institute, Inc. |
Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents
|
CA3139809A1
(en)
|
2019-05-10 |
2020-11-19 |
Takeda Pharmaceutical Company Limited |
Antibody drug conjugates
|
TW202045711A
(zh)
|
2019-06-13 |
2020-12-16 |
美商安進公司 |
生物製品製造中基於生物量之自動灌注控制
|
JP2022537289A
(ja)
|
2019-06-17 |
2022-08-25 |
ビステラ, インコーポレイテッド |
Cd138に対するヒト化抗体分子およびその使用
|
AU2020317009A1
(en)
|
2019-07-19 |
2022-02-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Chimeric antigen receptors containing Glypican 2 binding domains
|
TW202118774A
(zh)
|
2019-07-26 |
2021-05-16 |
美商威特拉公司 |
介白素-2藥劑及其用途
|
WO2021018941A1
(en)
|
2019-07-31 |
2021-02-04 |
Glaxosmithkline Intellectual Property Development Limited |
Methods of treating cancer
|
KR20220041915A
(ko)
|
2019-08-06 |
2022-04-01 |
글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 |
바이오제약 조성물 및 관련 방법
|
EP4031658A1
(de)
|
2019-08-07 |
2022-07-27 |
DB Biotech, AS |
Verbesserte meerrettichperoxidase-polypeptide
|
CN114555637A
(zh)
|
2019-08-12 |
2022-05-27 |
比昂生物制剂公司 |
针对ilt2的抗体及其用途
|
EP4025303A1
(de)
|
2019-09-04 |
2022-07-13 |
Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) |
Herv-inhibitoren zur verwendung bei der behandlung von tauopathien
|
WO2021043961A1
(en)
|
2019-09-06 |
2021-03-11 |
Glaxosmithkline Intellectual Property Development Limited |
Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy
|
WO2021046293A1
(en)
|
2019-09-06 |
2021-03-11 |
Glaxosmithkline Intellectual Property Development Limited |
Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and tremelimumab
|
CA3152946A1
(en)
|
2019-09-10 |
2021-03-18 |
Amgen Inc. |
Purification method for bispecific antigen-binding polypeptides with enhanced protein l capture dynamic binding capacity
|
EP3792632A1
(de)
|
2019-09-16 |
2021-03-17 |
Vito NV |
Immuntherapiemarker
|
AR120079A1
(es)
|
2019-09-19 |
2022-02-02 |
Seattle Genetics Inc |
Liberación selectiva de fármacos de conjugados internalizados de compuestos biológicamente activos
|
WO2021058711A2
(en)
|
2019-09-27 |
2021-04-01 |
Glaxosmithkline Intellectual Property Development Limited |
Antigen binding proteins
|
CN114746119A
(zh)
|
2019-09-27 |
2022-07-12 |
詹森生物科技公司 |
抗-ceacam抗体及其用途
|
JP2022550851A
(ja)
|
2019-10-04 |
2022-12-05 |
シージェン インコーポレイテッド |
カンプトテシンペプチドコンジュゲート
|
WO2021067820A1
(en)
|
2019-10-04 |
2021-04-08 |
Seagen Inc. |
Formulation of antibody-drug conjugate
|
WO2021077051A1
(en)
|
2019-10-18 |
2021-04-22 |
Immunomic Therapeutics, Inc |
Improved lamp constructs comprising cancer antigens
|
BR112022007179A2
(pt)
|
2019-10-21 |
2022-08-23 |
Novartis Ag |
Inibidores de tim-3 e usos dos mesmos
|
AU2020370086A1
(en)
|
2019-10-21 |
2022-05-19 |
Novartis Ag |
Combination therapies with venetoclax and TIM-3 inhibitors
|
CA3156683A1
(en)
|
2019-11-13 |
2021-05-20 |
Amgen Inc. |
METHOD FOR REDUCING AGGREGATE FORMATION IN DOWNSTREAM PROCESSING OF BI-SPECIFIC ANTIGEN-BINDING MOLECULES
|
US20230190922A1
(en)
|
2019-11-20 |
2023-06-22 |
Bavarian Nordic A/S |
Recombinant MVA Viruses for Intratumoral and/or Intravenous Administration for Treating Cancer
|
GB201919061D0
(en)
|
2019-12-20 |
2020-02-05 |
Ucb Biopharma Sprl |
Multi-specific antibody
|
GB201919058D0
(en)
|
2019-12-20 |
2020-02-05 |
Ucb Biopharma Sprl |
Multi-specific antibodies
|
IL293640A
(en)
|
2019-12-20 |
2022-08-01 |
Amgen Inc |
CD40 antagonistic mesothelin-targeted multispecific antibody constructs for the treatment of solid tumors
|
EP4076660A1
(de)
|
2019-12-20 |
2022-10-26 |
Novartis AG |
Verwendung von anti-tgf-beta-antikörpern und checkpoint-inhibitoren zur behandlung von proliferativen erkrankungen
|
GB201919062D0
(en)
|
2019-12-20 |
2020-02-05 |
Ucb Biopharma Sprl |
Antibody
|
EP4081554A1
(de)
|
2019-12-27 |
2022-11-02 |
Affimed GmbH |
Verfahren zur herstellung eines bispezifischen fcyriii-x-cd30-antikörper-konstrukts
|
TW202138388A
(zh)
|
2019-12-30 |
2021-10-16 |
美商西根公司 |
以非海藻糖苷化抗-cd70抗體治療癌症之方法
|
WO2021138407A2
(en)
|
2020-01-03 |
2021-07-08 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to cd33 and uses thereof
|
US20230090552A1
(en)
|
2020-01-08 |
2023-03-23 |
Synthis Therapeutics, Inc. |
Alk5 inhibitor conjugates and uses thereof
|
CA3167427A1
(en)
|
2020-01-11 |
2021-07-15 |
Scholar Rock, Inc. |
Tgfb inhibitors and use thereof
|
US20230050148A1
(en)
|
2020-01-11 |
2023-02-16 |
Scholar Rock, Inc. |
Tgf-beta inhibitors and use thereof
|
TW202140553A
(zh)
|
2020-01-13 |
2021-11-01 |
美商威特拉公司 |
C5ar1抗體分子及其用途
|
US20230058489A1
(en)
|
2020-01-17 |
2023-02-23 |
Novartis Ag |
Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
|
US20230093169A1
(en)
|
2020-01-22 |
2023-03-23 |
Amgen Research (Munch) Gmbh |
Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
|
JP2023512023A
(ja)
|
2020-01-28 |
2023-03-23 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド |
併用療法及びその使用及び方法
|
GB202001447D0
(en)
|
2020-02-03 |
2020-03-18 |
Ucb Biopharma Sprl |
Antibodies
|
KR20230004453A
(ko)
|
2020-02-25 |
2023-01-06 |
메디보스턴 리미티드 |
캄프토테신 유도체 및 이의 접합체
|
WO2021183861A1
(en)
|
2020-03-12 |
2021-09-16 |
Amgen Inc. |
Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor
|
CA3175275A1
(en)
|
2020-03-19 |
2021-09-23 |
Amgen Inc. |
Antibodies against mucin 17 and uses thereof
|
US11815513B2
(en)
|
2020-04-01 |
2023-11-14 |
Institut Pasteur |
Severe acute respiratory syndrome (SARS)-associated coronavirus diagnostics
|
US20210311054A1
(en)
|
2020-04-01 |
2021-10-07 |
Institut Pasteur |
Severe acute respiratory syndrome (sars) - associated coronavirus diagnostics
|
CN116710146A
(zh)
|
2020-04-03 |
2023-09-05 |
威特拉公司 |
抗体分子-药物偶联物及其用途
|
KR20220164787A
(ko)
|
2020-04-06 |
2022-12-13 |
이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. |
암 및 감염의 치료를 위한 NKp46에 대한 항체 및 이의 작제물
|
BR112022020332A2
(pt)
|
2020-04-10 |
2022-12-13 |
Seagen Inc |
Composto conjugado anticorpo-droga, composição, método de tratamento de câncer e de um distúrbio autoimune
|
WO2021209358A1
(en)
|
2020-04-14 |
2021-10-21 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatment for cancer based upon an icos antibody and a pd-l1 antibody tgf-beta-receptor fusion protein
|
WO2021209357A1
(en)
|
2020-04-14 |
2021-10-21 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatment for cancer involving anti-icos and anti-pd1 antibodies, optionally further involving anti-tim3 antibodies
|
JP2023521227A
(ja)
|
2020-04-14 |
2023-05-23 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド |
癌の併用療法
|
CN115667300A
(zh)
|
2020-04-17 |
2023-01-31 |
硕腾服务有限责任公司 |
猫抗体变异体
|
EP4136106A1
(de)
|
2020-04-17 |
2023-02-22 |
Zoetis Services LLC |
Hundeantikörpervarianten
|
WO2021209824A1
(en)
|
2020-04-17 |
2021-10-21 |
Institut Pasteur |
Methods and products for serological analysis of sars-cov-2 infection
|
WO2021217085A1
(en)
|
2020-04-24 |
2021-10-28 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to t cell related cancer cells and uses thereof
|
WO2021220215A1
(en)
|
2020-05-01 |
2021-11-04 |
Novartis Ag |
Engineered immunoglobulins
|
US20230167193A1
(en)
|
2020-05-01 |
2023-06-01 |
Novartis Ag |
Immunoglobulin variants
|
AU2021275049A1
(en)
|
2020-05-19 |
2022-12-22 |
Amgen Inc. |
MAGEB2 binding constructs
|
WO2021239666A1
(en)
|
2020-05-26 |
2021-12-02 |
Diaccurate |
Therapeutic methods
|
US20240209085A1
(en)
|
2020-05-29 |
2024-06-27 |
Amgen Inc. |
Adverse effects-mitigating administration of a bispecific construct binding to cd33 and cd3
|
EP4161653A1
(de)
|
2020-06-03 |
2023-04-12 |
Bionecure Therapeutics, Inc. |
Trophoblastzelloberflächenantigen-2 (trop-2)-antikörper
|
BR112022026639A2
(pt)
|
2020-06-24 |
2023-05-09 |
Visterra Inc |
Moléculas de anticorpos para april e seus usos
|
WO2022005883A1
(en)
|
2020-06-29 |
2022-01-06 |
Zoetis Services Llc |
Feline antibody variants for improving stability
|
US20230256114A1
(en)
|
2020-07-07 |
2023-08-17 |
Bionecure Therapeutics, Inc. |
Novel maytansinoids as adc payloads and their use for the treatment of cancer
|
WO2022008976A1
(en)
|
2020-07-10 |
2022-01-13 |
Institut Pasteur |
Use of gdf11 to diagnose and treat anxiety and depression
|
WO2022026592A2
(en)
|
2020-07-28 |
2022-02-03 |
Celltas Bio, Inc. |
Antibody molecules to coronavirus and uses thereof
|
EP4193153A1
(de)
|
2020-08-06 |
2023-06-14 |
Bioverativ USA Inc. |
Entzündungszytokine und ermüdung bei patienten mit komplementvermittelter erkrankung
|
CA3190634A1
(en)
|
2020-08-12 |
2022-02-17 |
Biond Biologics Ltd. |
Antibodies against ilt2 and use thereof
|
WO2022046922A2
(en)
|
2020-08-26 |
2022-03-03 |
Marengo Therapeutics, Inc. |
Antibody molecules that bind to nkp30 and uses thereof
|
JP2023540248A
(ja)
|
2020-08-26 |
2023-09-22 |
マレンゴ・セラピューティクス,インコーポレーテッド |
Trbc1またはtrbc2を検出する方法
|
CA3190755A1
(en)
|
2020-08-26 |
2022-03-03 |
Andreas Loew |
Multifunctional molecules that bind to calreticulin and uses thereof
|
US20230338587A1
(en)
|
2020-08-31 |
2023-10-26 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
EP4204021A1
(de)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Verfahren zur behandlung von psma-exprimierenden krebsarten
|
CA3192526A1
(en)
|
2020-09-04 |
2022-03-10 |
Rutgers, The State University Of New Jersey |
Sars-cov-2 vaccines and antibodies
|
WO2022058621A1
(en)
|
2020-09-21 |
2022-03-24 |
Theravectys |
High throughput methods and products for sars-cov-2 sero-neutralization assay
|
CA3194936A1
(en)
|
2020-09-28 |
2022-03-31 |
Zoetis Services Llc |
Canine antibody variants
|
TW202413413A
(zh)
|
2020-09-29 |
2024-04-01 |
美商碩騰服務公司 |
貓抗體變異體
|
DE102020125465A1
(de)
|
2020-09-29 |
2022-03-31 |
Immatics Biotechnologies Gmbh |
Amidierte Peptide und ihre deamidierten Gegenstücke, die durch nicht-HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
|
DE102020125457A1
(de)
|
2020-09-29 |
2022-03-31 |
Immatics Biotechnologies Gmbh |
Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
|
TW202229312A
(zh)
|
2020-09-29 |
2022-08-01 |
德商英麥提克生物技術股份有限公司 |
由非hla-a*02顯露以用於不同類型癌症之免疫治療的醯胺化肽及其脫醯胺化對應物
|
CN116368154A
(zh)
|
2020-10-08 |
2023-06-30 |
阿菲姆德股份有限公司 |
三特异性结合剂
|
MX2023004436A
(es)
|
2020-10-15 |
2023-05-08 |
UCB Biopharma SRL |
Moleculas de union que multimerizan cd45.
|
WO2022081436A1
(en)
|
2020-10-15 |
2022-04-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
|
WO2022087274A1
(en)
|
2020-10-21 |
2022-04-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies that neutralize type-i interferon (ifn) activity
|
EP4237081A1
(de)
|
2020-11-02 |
2023-09-06 |
UCB Biopharma SRL |
Verwendung von anti-trem1-neutralisierenden antikörpern zur behandlung neurodegenerativer erkrankungen von motoneuronen
|
EP4240407A1
(de)
|
2020-11-06 |
2023-09-13 |
Amgen Inc. |
Antigenbindende domäne mit reduzierter clipping-rate
|
JP2023547661A
(ja)
|
2020-11-06 |
2023-11-13 |
アムジエン・インコーポレーテツド |
Cd3に結合するポリペプチド構築物
|
WO2022096716A2
(en)
|
2020-11-06 |
2022-05-12 |
Amgen Inc. |
Multitargeting bispecific antigen-binding molecules of increased selectivity
|
WO2022096700A1
(en)
|
2020-11-06 |
2022-05-12 |
Amgen Research (Munich) Gmbh |
Polypeptide constructs selectively binding to cldn6 and cd3
|
WO2022097117A1
(en)
|
2020-11-09 |
2022-05-12 |
Takeda Pharmaceutical Company Ltd. |
Antibody drug conjugates
|
KR20230110297A
(ko)
|
2020-11-20 |
2023-07-21 |
조에티스 서비시즈 엘엘씨 |
소 항체 변이체
|
AU2021391924A1
(en)
|
2020-12-04 |
2023-06-22 |
The General Hospital Corporation |
Methods of using interleukin-2 agents
|
JP2023551983A
(ja)
|
2020-12-07 |
2023-12-13 |
ユーシービー バイオファルマ エスアールエル |
インターロイキン-22に対する抗体
|
MX2023006650A
(es)
|
2020-12-07 |
2023-06-21 |
UCB Biopharma SRL |
Anticuerpos multiespecificos y combinaciones de anticuerpos.
|
AU2021400322A1
(en)
|
2020-12-18 |
2023-06-22 |
Zoetis Services Llc |
Mutations in feline antibody constant regions
|
EP4277665A1
(de)
|
2021-01-13 |
2023-11-22 |
Memorial Sloan Kettering Cancer Center |
Anti-dll3-antikörper-wirkstoff-konjugat
|
AU2022207708A1
(en)
|
2021-01-13 |
2023-07-27 |
Daiichi Sankyo Company, Limited |
Antibody-pyrrolobenzodiazepine derivative conjugate
|
TW202241925A
(zh)
|
2021-01-15 |
2022-11-01 |
德商英麥提克生物技術股份有限公司 |
用於不同類型癌症免疫治療的hla展示肽
|
EP4277904A1
(de)
|
2021-01-15 |
2023-11-22 |
Seagen Inc. |
Immunmodulatorische antikörper-wirkstoff-konjugate
|
KR20230147072A
(ko)
|
2021-01-20 |
2023-10-20 |
비스테라, 인크. |
인터류킨-2 돌연변이체 및 이의 용도
|
JP2024504696A
(ja)
|
2021-01-20 |
2024-02-01 |
バイオアントレ エルエルシー |
Ctla4結合性タンパク質およびがんを処置する方法
|
CA3208998A1
(en)
|
2021-01-22 |
2022-07-28 |
Steven Kerrigan |
Treatment of coronavirus
|
EP4284825A2
(de)
|
2021-01-28 |
2023-12-06 |
Zoetis Services LLC |
Mutationen in konstanten regionen von hundeantikörpern
|
WO2022162569A1
(en)
|
2021-01-29 |
2022-08-04 |
Novartis Ag |
Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
|
WO2022170002A1
(en)
|
2021-02-03 |
2022-08-11 |
Seagen Inc. |
Immunostimulatory compounds and conjugates
|
JP2024507124A
(ja)
|
2021-02-11 |
2024-02-16 |
ネクチン セラピューティクス リミテッド |
Cd112rに対する抗体およびその使用
|
WO2022182872A2
(en)
|
2021-02-24 |
2022-09-01 |
Alladapt Immunotherapeutics, Inc. |
Compositions and methods for identification of cross-reactive allergenic proteins and treatment of allergies
|
WO2022186773A1
(en)
|
2021-03-01 |
2022-09-09 |
Aslan Pharmaceuticals Pte Ltd |
TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF IN AN ALLERGIC POPULATION
|
WO2022186772A1
(en)
|
2021-03-01 |
2022-09-09 |
Aslan Pharmaceuticals Pte Ltd |
TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF
|
EP4301777A1
(de)
|
2021-03-02 |
2024-01-10 |
Dana-Farber Cancer Institute, Inc. |
Verfahren zur behandlung von erythrozytenerkrankungen
|
EP4308171A1
(de)
|
2021-03-18 |
2024-01-24 |
Seagen Inc. |
Selektive wirkstofffreisetzung aus internalisierten konjugaten biologisch aktiver verbindungen
|
CN117321418A
(zh)
|
2021-03-18 |
2023-12-29 |
诺华股份有限公司 |
癌症生物标志物及其使用方法
|
BR112023018676A2
(pt)
|
2021-03-18 |
2023-10-10 |
Seagen Inc |
Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco
|
WO2022204581A2
(en)
|
2021-03-26 |
2022-09-29 |
Scholar Rock, Inc. |
Tgf-beta inhibitors and use thereof
|
US20240166747A1
(en)
|
2021-03-31 |
2024-05-23 |
Glazosmithkline Intellectual Property Development Limited |
Antigen binding proteins and combinations thereof
|
CN117241828A
(zh)
|
2021-03-31 |
2023-12-15 |
美国比奥维拉迪维股份有限公司 |
减少冷凝集素病患者的手术相关溶血
|
EP4067381A1
(de)
|
2021-04-01 |
2022-10-05 |
Julius-Maximilians-Universität Würzburg |
Neue tnfr2-bindende moleküle
|
CA3215594A1
(en)
|
2021-04-02 |
2022-10-06 |
Agnieszka KIELCZEWSKA |
Mageb2 binding constructs
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
|
JP2024515591A
(ja)
|
2021-04-08 |
2024-04-10 |
マレンゴ・セラピューティクス,インコーポレーテッド |
Tcrに結合する多機能性分子およびその使用
|
CA3214934A1
(en)
|
2021-04-12 |
2022-10-20 |
Madhavan Nallani |
Polymersomes comprising a soluble encapsulated polynucleotide and an ionizable lipid as well as methods of making and uses thereof
|
EP4334355A1
(de)
|
2021-05-03 |
2024-03-13 |
UCB Biopharma SRL |
Antikörper
|
CA3217180A1
(en)
|
2021-05-06 |
2022-11-10 |
Amgen Research (Munich) Gmbh |
Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
|
WO2022251850A1
(en)
|
2021-05-28 |
2022-12-01 |
Seagen Inc. |
Anthracycline antibody conjugates
|
WO2022256723A2
(en)
|
2021-06-03 |
2022-12-08 |
Scholar Rock, Inc. |
Tgf-beta inhibitors and therapeutic use thereof
|
WO2022261183A2
(en)
|
2021-06-08 |
2022-12-15 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
|
JP2024524159A
(ja)
|
2021-06-23 |
2024-07-05 |
スカラー ロック インコーポレイテッド |
代謝障害の治療における使用のためのglp-1経路活性化剤と組み合わせたミオスタチン経路阻害剤
|
WO2023278377A1
(en)
|
2021-06-29 |
2023-01-05 |
Seagen Inc. |
Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist
|
KR20240034234A
(ko)
|
2021-07-14 |
2024-03-13 |
2세븐티 바이오, 인코포레이티드 |
항체로부터의 결합 도메인에 융합된 조작된 t 세포 수용체
|
WO2023007023A1
(en)
|
2021-07-30 |
2023-02-02 |
Affimed Gmbh |
Duplexbodies
|
CN117794954A
(zh)
|
2021-08-03 |
2024-03-29 |
葛兰素史密斯克莱知识产权发展有限公司 |
生物药物组合物和稳定同位素标记肽图谱方法
|
GB202111905D0
(en)
|
2021-08-19 |
2021-10-06 |
UCB Biopharma SRL |
Antibodies
|
WO2023025927A1
(en)
|
2021-08-26 |
2023-03-02 |
Glycanostics S.R.O |
Glycoprotein biomarkers for diagnosing cancer
|
CA3231890A1
(en)
|
2021-09-14 |
2023-03-23 |
Jan Tkac |
Use of lectins to determine mammaglobin-a glycoforms in breast cancer
|
EP4405396A2
(de)
|
2021-09-20 |
2024-07-31 |
Voyager Therapeutics, Inc. |
Zusammensetzungen und verfahren zur behandlung von her2-positivem krebs
|
WO2023048651A1
(en)
|
2021-09-27 |
2023-03-30 |
Aslan Pharmaceuticals Pte Ltd |
Method for treatment of moderate to severe atoptic dematitis
|
WO2023048650A1
(en)
|
2021-09-27 |
2023-03-30 |
Aslan Pharmaceuticals Pte Ltd |
TREATMENT OF PRURITIS EMPLOYING ANTI-IL13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF
|
GB202115122D0
(en)
|
2021-10-21 |
2021-12-08 |
Dualyx Nv |
Binding molecules targeting IL-2 receptor
|
TW202333784A
(zh)
|
2021-10-29 |
2023-09-01 |
新加坡商亞獅康私人有限公司 |
抗il13r抗體調配物
|
IL312060A
(en)
|
2021-11-03 |
2024-06-01 |
Affimed Gmbh |
Bispecific CD16A binders
|
KR20240099407A
(ko)
|
2021-11-03 |
2024-06-28 |
아피메트 게엠베하 |
이중특이적 cd16a 결합제
|
WO2023079058A1
(en)
|
2021-11-05 |
2023-05-11 |
Yokogawa Insilico Biotechnology Gmbh |
Cell culture with reduced production of lactate
|
WO2023092004A1
(en)
|
2021-11-17 |
2023-05-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
US20230348614A1
(en)
|
2021-11-24 |
2023-11-02 |
Visterra, Inc. |
Engineered antibody molecules to cd138 and uses thereof
|
WO2023097119A2
(en)
|
2021-11-29 |
2023-06-01 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions to modulate riok2
|
CA3238574A1
(en)
|
2021-12-01 |
2023-06-08 |
Gregory Babcock |
Methods of using interleukin-2 agents
|
WO2023105528A1
(en)
|
2021-12-12 |
2023-06-15 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Antibodies specific to ceacam1
|
WO2023118508A1
(en)
|
2021-12-23 |
2023-06-29 |
Bavarian Nordic A/S |
Recombinant mva viruses for intraperitoneal administration for treating cancer
|
WO2023140780A1
(en)
|
2022-01-24 |
2023-07-27 |
Aslan Pharmaceuticals Pte Ltd. |
Method of treating inflammatory disease
|
WO2023148598A1
(en)
|
2022-02-02 |
2023-08-10 |
Pfizer Inc. |
Cysteine prototrophy
|
US20230383010A1
(en)
|
2022-02-07 |
2023-11-30 |
Visterra, Inc. |
Anti-idiotype antibody molecules and uses thereof
|
WO2023163659A1
(en)
|
2022-02-23 |
2023-08-31 |
Aslan Pharmaceuticals Pte Ltd |
Glycosylated form of anti-il13r antibody
|
WO2023175614A1
(en)
|
2022-03-15 |
2023-09-21 |
Yeda Research And Development Co. Ltd. |
Anti glucocorticoid-induced tnfr-related (gitr) protein antibodies and uses thereof
|
TW202400137A
(zh)
|
2022-03-17 |
2024-01-01 |
美商思進公司 |
喜樹鹼偶聯物
|
WO2023201201A1
(en)
|
2022-04-10 |
2023-10-19 |
Immunomic Therapeutics, Inc. |
Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof
|
WO2023212518A1
(en)
|
2022-04-25 |
2023-11-02 |
Visterra, Inc. |
Antibody molecules to april and uses thereof
|
WO2023215740A1
(en)
|
2022-05-06 |
2023-11-09 |
Seagen Inc. |
Immunomodulatory antibody-drug conjugates
|
WO2023218027A1
(en)
|
2022-05-12 |
2023-11-16 |
Amgen Research (Munich) Gmbh |
Multichain multitargeting bispecific antigen-binding molecules of increased selectivity
|
WO2023220695A2
(en)
|
2022-05-13 |
2023-11-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
WO2023223092A1
(en)
|
2022-05-18 |
2023-11-23 |
Institut Pasteur |
Identification of a human circovirus
|
WO2023240287A1
(en)
|
2022-06-10 |
2023-12-14 |
Bioentre Llc |
Combinations of ctla4 binding proteins and methods of treating cancer
|
WO2023245048A1
(en)
|
2022-06-15 |
2023-12-21 |
Bioverativ Usa Inc. |
Anti-complement c1s antibody formulation
|
EP4296279A1
(de)
|
2022-06-23 |
2023-12-27 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Anti-transthyretin(ttr)-bindende proteine und ihre verwendungen
|
US20240025978A1
(en)
|
2022-06-24 |
2024-01-25 |
Bioverativ Usa Inc. |
Methods for treating complement-mediated diseases
|
GB202210679D0
(en)
|
2022-07-21 |
2022-09-07 |
Dualyx Nv |
Binding molecules targeting il-12rb2
|
US20240108744A1
(en)
|
2022-07-27 |
2024-04-04 |
Mediboston Limited |
Auristatin derivatives and conjugates thereof
|
WO2024030577A1
(en)
|
2022-08-03 |
2024-02-08 |
Seagen Inc. |
Immunostimulatory anti-pd-l1-drug conjugates
|
WO2024030976A2
(en)
|
2022-08-03 |
2024-02-08 |
Voyager Therapeutics, Inc. |
Compositions and methods for crossing the blood brain barrier
|
EP4321522A1
(de)
|
2022-08-12 |
2024-02-14 |
Seagen Inc. |
Zytotoxische verbindungen und konjugate davon
|
WO2024043837A1
(en)
|
2022-08-26 |
2024-02-29 |
Aslan Pharmaceuticals Pte Ltd |
High concentration anti-il13r antibody formulation
|
WO2024054157A1
(en)
|
2022-09-06 |
2024-03-14 |
Aslan Pharmaceuticals Pte Ltd |
Treatment for sleep loss or sleep disturbance in patients with dermatitis
|
WO2024059675A2
(en)
|
2022-09-14 |
2024-03-21 |
Amgen Inc. |
Bispecific molecule stabilizing composition
|
WO2024062074A1
(en)
|
2022-09-21 |
2024-03-28 |
Sanofi Biotechnology |
Humanized anti-il-1r3 antibody and methods of use
|
WO2024129756A1
(en)
|
2022-12-13 |
2024-06-20 |
Seagen Inc. |
Site-specific engineered cysteine antibody drug conjugates
|
WO2024138076A1
(en)
|
2022-12-22 |
2024-06-27 |
Scholar Rock, Inc. |
Selective and potent inhibitory antibodies of myostatin activation
|
WO2024133858A1
(en)
|
2022-12-22 |
2024-06-27 |
Julius-Maximilians-Universität-Würzburg |
Antibodies for use as coagulants
|